

REFINITIV

DELTA REPORT

10-Q

KERN - AKERNA CORP.

10-Q - SEPTEMBER 30, 2023 COMPARED TO 10-Q - JUNE 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS 1665

■ CHANGES	187
■ DELETIONS	921
■ ADDITIONS	557

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

□ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023 September 30, 2023

OR

□ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from / to

Commission file number 001-39096

AKERNA CORP.

(Exact name of registrant as specified in its charter)

Delaware

83-2242651

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1550 Larimer Street, #246 Denver, Colorado

80202

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (888)492-3540
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	KERN	Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase one share of common stock	KERNW	Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) Yes No

As of August 11, 2023 November 14, 2023, there were 7,802,018 shares of the registrant's common stock, par value \$0.0001 per share, outstanding.

INDEX

PART I		FINANCIAL INFORMATION	
Item 1.		<u>Condensed Consolidated Balance Sheets (unaudited)</u>	1
		<u>Condensed Consolidated Statements of Operations (unaudited)</u>	2
		<u>Condensed Consolidated Statements of Comprehensive Loss (unaudited)</u>	3
		<u>Condensed Consolidated Statements of Changes in Stockholders' Stockholders' Deficit (unaudited)</u>	4
		<u>Condensed Consolidated Statements of Cash Flows (unaudited)</u>	6
		<u>Notes to Condensed Consolidated Financial Statements (unaudited)</u>	7
Item 2.		<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	24
Item 3.		<u>Quantitative and Qualitative Disclosures About Market Risk</u>	36
Item 4.		<u>Controls and Procedures</u>	37
			41
PART II		OTHER INFORMATION	
Item 1.		<u>Legal Proceedings</u>	39
Item 1A.		<u>Risk Factors</u>	39
Item 2.		<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	41
Item 3.		<u>Defaults Upon Senior Securities</u>	41
Item 4.		<u>Mine Safety Disclosures</u>	41
Item 5.		<u>Other Information</u>	41
Item 6.		<u>Exhibits</u>	42
		<u>SIGNATURES</u>	44
			48

AKERNA CORP.
Condensed Consolidated Balance Sheets

(unaudited)

(unaudited)

	June 30, 2023	December 31, 2022
Assets		
Current assets		
Cash	\$ 828,133	\$ 877,755
Restricted cash	500,000	7,000,000
Accounts receivable, net	249,797	674,626
Prepaid expenses and other current assets	827,304	1,209,623
Assets held for sale	<u>—</u>	<u>5,130,028</u>
Total current assets	2,405,234	14,892,032
Fixed assets, net	33,604	48,879
Capitalized software, net	344,302	654,556
Intangible assets, net	1,920,000	2,164,722
Goodwill	1,708,303	1,708,303
Total assets	<u>\$ 6,411,443</u>	<u>\$ 19,468,492</u>
Liabilities and Stockholders' Deficit		
Current liabilities		
Accounts payable, accrued expenses and other accrued liabilities	\$ 3,995,736	\$ 4,426,419
Contingent consideration payable	<u>September 30, 2023</u>	<u>December 31, 2022</u>
Current portion of deferred revenue	<u>313,100</u>	<u>568,771</u>
Assets		
Current portion of long-term debt	7,770,543	13,200,000
Current assets		
Liabilities held for sale		
Cash	<u>209,577</u>	<u>877,755</u>
Total current liabilities	<u>12,079,379</u>	<u>22,725,418</u>
Restricted cash	<u>—</u>	<u>7,000,000</u>
Accounts receivable, net	<u>252,951</u>	<u>674,626</u>
Prepaid expenses and other current assets	<u>780,618</u>	<u>1,209,623</u>
Assets held for sale, less current portion	<u>2,494,457</u>	<u>5,130,028</u>
Total current assets	<u>14,524,834</u>	<u>24,892,032</u>
Fixed assets, net	27,425	48,879
Commitments and contingencies (Note 8)	213,766	654,556
Capitalized software, net	1,880,000	2,164,722
Intangible assets, net	816,200	1,708,303
Stockholders' deficit		
Preferred stock, par value \$0.0001; 5,000,000 shares authorized, 1 share special voting preferred stock issued and outstanding at June 30, 2023 and December 31, 2022	<u>\$ 4,180,537</u>	<u>\$ 19,468,492</u>
Liabilities and stockholders' deficit	<u>—</u>	<u>—</u>
Liabilities and stockholders' deficit, less current portion	<u>1,929,514</u>	<u>2,426,419</u>
Current liabilities, less current portion	<u>1,929,514</u>	<u>2,426,419</u>
Commitments and contingencies (Note 8)	—	2,283,806
Common stock, par value \$0.0001; 150,000,000 shares authorized, 6,999,290 and 4,602,780 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	469,874	568,771
Current portion of long-term debt	7,733,271	16,309,989
Assets held for sale	162,602,715	162,602,715
Accumulated other comprehensive income	337,103	2,249,722
Total current liabilities	12,529,872	22,725,218
Accumulated deficit	(173,122,425)	(167,555,846)
Total stockholders' deficit	(8,162,393)	(4,825,528)
Deferred revenue, noncurrent	—	(161,869)
Total long-term debt less current portion	<u>6,411,443</u>	<u>\$ 19,468,492</u>
Total liabilities	<u>13,379,601</u>	<u>24,294,020</u>
Commitments and contingencies (Note 8)	—	—
Stockholders' deficit	—	—

Preferred stock, par value \$0.0001; 5,000,000 shares authorized, 1 share special voting preferred stock issued and outstanding at September 30, 2023 and December 31, 2022	—	—
Special voting preferred stock, par value \$0.0001; 1 share authorized, issued and outstanding as of September 30, 2023 and December 31, 2022, with \$1 preference in liquidation; exchangeable shares, no par value, 249,504 and 285,672 shares issued and outstanding as of September 30, 2023 and December 31, 2022	1,907,941	2,185,391
Common stock, par value \$0.0001; 150,000,000 shares authorized, 10,002,018 and 4,602,780 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	1,000	460
Additional paid-in capital	164,314,084	160,207,367
Accumulated other comprehensive income	295,274	347,100
Accumulated deficit	(175,717,363)	(167,565,846)
Total stockholders' deficit	(9,199,064)	(4,825,528)
Total liabilities and stockholders' deficit	\$ 4,180,537	\$ 19,468,492

The accompanying notes are an integral part of these condensed consolidated financial statements

AKERNA CORP.
Condensed Consolidated Statements of Operations
(unaudited)

	For the Three Months Ended								For the Six Months Ended								For the Three Months Ended			
	June 30,				June 30,				September 30,		September 30,		September 30,		September 30,		September 30,			
		2023	2022		2023	2022		2023	2022		2023	2022		2023	2022		2023	2022		
Revenue																				
Software	\$	2,242,792	\$ 3,366,333	\$	4,839,554	\$	7,169,085	\$	2,069,845	\$ 2,980,926	\$	6,909,399	\$ 10,150,011							
Consulting		39,800	115,300		39,800		542,309		6,200	76,500		46,000	618,809							
Other revenue		5,276	8,043		11,203		23,362		6,508	6,953		17,710	30,315							
Total revenue		2,287,868	3,489,676		4,890,557		7,734,756		2,082,553	3,064,379		6,973,109	10,799,135							
Cost of revenue		962,896	1,175,261		2,013,977		2,698,270		974,711	1,476,787		2,988,688	4,175,056							
Gross profit		1,324,972	2,314,415		2,876,580		5,036,486		1,107,842	1,587,592		3,984,421	6,624,079							
Operating expenses																				
Product development		659,287	1,275,372		1,504,765		2,991,119		649,070	959,186		2,153,834	3,950,305							
Sales and marketing		650,358	1,979,091		1,431,849		4,030,224		566,147	954,759		1,977,996	4,984,983							
General and administrative		1,495,947	2,658,017		3,057,848		4,580,348		1,401,101	1,830,663		4,458,949	6,409,564							
Depreciation and amortization		278,456	1,442,560		570,252		2,924,005		176,715	1,551,480		746,966	4,475,485							
Impairment of long-lived assets		—	15,115,843		—		30,562,944		892,103	—		892,103	30,562,944							
Total operating expenses		3,084,048	22,470,883		6,564,714		45,088,640		3,685,136	5,296,088		10,249,849	50,383,281							
Loss from operations		(1,759,076)	(20,156,468)		(3,688,134)		(40,052,154)		(2,577,294)	(3,708,496)		(6,265,427)	(43,759,202)							
Other (expense) income																				
Interest (expense) income, net		(227,055)	(212,987)		(714,371)		(213,727)		(202,644)	(395,422)		(917,015)	(609,150)							
Change in fair value of convertible notes		(893,000)	(294,000)		(1,048,457)		(1,727,000)		185,000	(1,113,000)		(863,457)	(2,840,000)							
Change in fair value of derivative liability		—	33,845		—		51,896		—	2,256		—	54,153							
Other expense, net		(202,820)	—		(202,820)		—		—	—		9,781	—							
Total other (expense) income		(1,322,875)	(473,142)		(1,965,648)		(1,888,831)		(17,644)	(1,506,166)		(1,770,691)	(3,394,997)							
Net loss from continuing operations before income taxes																				
Income tax benefit on continuing operations		(3,081,951)	(20,629,610)		(5,653,782)		(41,940,985)		(2,594,938)	(5,214,662)		(8,036,118)	(47,154,199)							
Net loss from continuing operations		(3,081,951)	(20,501,568)		(5,653,782)		(41,713,499)		(2,594,938)	(5,173,996)		(8,036,118)	(46,886,047)							
Net gain (loss) from discontinued operations		—	(9,064,379)		97,203		(9,805,341)		—	2,869,908		(115,398)	(6,936,881)							
Net loss	\$	(3,081,951)	\$ (29,565,947)	\$	(5,556,579)	\$	(51,518,840)		\$ (2,594,938)	\$ (2,304,088)	\$	\$ (8,151,516)	\$ (53,822,928)							
Basic and diluted weighted average common shares outstanding		5,969,086	1,773,889		5,663,424		1,684,734		8,195,393	3,883,847		6,486,669	2,421,262							
Basic and diluted loss per common share from continuing operations	\$	(0.52)	\$ (11.56)	\$ (1.00)	\$ (24.76)				\$ (0.32)	\$ (1.33)	\$ (1.24)	\$ (19.36)								
Basic and diluted earnings (loss) per common share from discontinued operations	\$	—	\$ (5.11)	\$ 0.02	\$ (5.82)				\$ —	\$ 0.74	\$ (0.02)	\$ (2.87)								
Basic and diluted loss per common share	\$	(0.52)	\$ (16.67)	\$ (0.98)	\$ (30.58)				\$ (0.32)	\$ (0.59)	\$ (1.26)	\$ (22.23)								

The accompanying notes are an integral part of these condensed consolidated financial statements

AKERNA CORP.
Condensed Consolidated Statements of Comprehensive Loss
(b unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
Net loss	\$ (3,081,951)	\$ (29,565,947)	\$ (5,556,579)	\$ (51,518,840)
Other comprehensive (loss) income				
Foreign currency translation				
Unrealized (loss) gain on convertible notes	<u>(25,000)</u>	<u>63,000</u>	<u>(39,000)</u>	<u>264,000</u>
Comprehensive loss	<u>\$ (3,096,951)</u>	<u>\$ (29,592,518)</u>	<u>\$ (5,596,576)</u>	<u>\$ (51,518,840)</u>
Net loss	\$ (2,594,938)	\$ (2,304,088)	\$ (8,151,516)	\$ (53,822,928)
Other comprehensive (loss) income				
Foreign currency translation	(38,829)	27,676	(9,826)	4,505
Unrealized (loss) gain on convertible notes	(3,000)	26,000	(42,000)	290,000
Comprehensive loss	<u>\$ (2,636,767)</u>	<u>\$ (2,250,412)</u>	<u>\$ (8,203,342)</u>	<u>\$ (53,528,423)</u>

The accompanying notes are an integral part of these condensed consolidated financial statements

AKERNA CORP.
Condensed Consolidated Statements of Changes in Stockholders' Stockholders' Deficit Deficit
For the Six Nine Months Ended June 30, 2023 September 30, 2023
(unaudited)

	Special Voting Preferred Stock		Common		Additional Paid-In Capital	Accumulated Other		Total Stockholders' Deficit
	Shares	Amount	Shares	Amount		Comprehensive Income	Accumulated Deficit	
Balance – January 1, 2023	285,672	\$ 2,185,391	4,602,780	\$ 460	\$ 160,207,367	\$ 347,100	(\$167,565,846)	\$ (4,825,528)
Conversion of exchangeable shares to common stock	(640)	(4,896)	32	—	4,896	—	—	—
Settlement of convertible notes	—	—	1,164,251	116	1,396,985	—	—	1,397,101
Stock-based compensation	—	—	—	—	109,133	—	—	109,133
Issuance of common stock upon vesting of restricted stock units	—	—	587	—	—	—	—	—
Foreign currency translation adjustments	—	(unaudited)	—	—	—	20,429	—	20,429
Unrealized loss on convertible notes	—	—	—	—	—	Accumulated (14,000)	—	(14,000)
Net loss	—	—	—	—	—	—	—	—
Balance – March 31, 2023	285,032	\$ 2,180,495	5,767,650	\$ 576	\$ 161,718,381	\$ 353,529	(\$170,040,474)	\$ (5,787,493)
Conversion of exchangeable shares to common stock	(32,808)	(250,981)	1,640	1	250,980	—	—	—
Balance – January 1, 2023	285,672	\$ 2,185,391	4,602,780	\$ 460	\$ 160,207,367	\$ 347,100	(\$167,565,846)	\$ (4,825,528)
Conversion of exchangeable shares to common stock	—	—	230,000	23	114,977	—	—	115,000
Settlement of convertible notes	(640)	(4,896)	32	—	4,896	108,477	—	108,477
Stock-based compensation	—	—	1,164,251	116	1,396,985	499,900	—	500,000
Shares issued in a private placement offering	—	—	1,000,000	—	—	8,574	—	8,574
Foreign currency translation adjustments	—	—	—	—	—	(25,000)	—	(25,000)
Unrealized loss on convertible notes	—	—	—	—	—	—	—	—
Issuance of common stock upon vesting of restricted stock units	—	—	587	—	—	—	(3,081,951)	(3,081,951)
Net loss	—	—	—	—	—	—	—	—
Balance – March 31, 2023	285,032	\$ 2,180,495	5,767,650	\$ 576	\$ 161,718,381	\$ 353,529	(\$170,040,474)	\$ (5,787,493)
Conversion of exchangeable shares to common stock	(32,808)	(250,981)	1,640	1	250,980	—	—	—
Settlement of convertible notes	—	—	230,000	23	114,977	—	—	115,000
Stock-based compensation	—	—	—	—	108,477	—	—	108,477
Shares issued in a private placement offering	—	—	1,000,000	100	499,900	—	—	500,000
Foreign currency translation adjustments	—	—	—	—	—	8,574	—	8,574
Unrealized loss on convertible notes	—	—	—	—	—	(25,000)	—	(25,000)
Net loss	—	—	—	—	—	—	(3,081,951)	(3,081,951)
Balance – June 30, 2023	252,224	\$ 1,929,514	6,999,290	\$ 700	\$ 162,692,715	\$ 337,103	(\$173,122,425)	\$ (8,162,393)
Conversion of exchangeable shares to common stock	(2,720)	(21,57)	141	—	21,573	—	—	—
Settlement of convertible notes	—	—	3,000,000	300	1,499,700	—	—	1,500,000
Stock-based compensation	—	—	—	—	100,096	—	—	100,096
Issuance of common stock upon vesting of restricted stock units	—	—	2,587	—	—	—	—	—
Foreign currency translation adjustments	—	—	—	—	—	(38,829)	—	(38,829)
Unrealized loss on convertible notes	—	—	—	—	—	(3,000)	—	(3,000)
Net loss	—	—	—	—	—	—	(2,594,938)	(2,594,938)
Balance – September 30, 2023	249,504	\$ 1,907,941	10,002,018	\$ 1,000	\$ 164,314,084	\$ 295,274	(\$175,717,363)	\$ (9,199,064)

The accompanying notes are an integral part of these condensed consolidated financial statements

AKERNA CORP.
Condensed Consolidated Statements of Changes in Stockholders' Equity
For the Six Nine Months Ended June 30, 2022
(unaudited)
September 30, 2022

									Accumulated		Total Stockholders' Equity		
	Special Voting Preferred Stock		Common		Additional Paid-In Capital		Other Comprehensive Income						
	Shares	Amount	Shares	Amount	Capital	Income	Accumulated Deficit	Total Stockholders' Equity					
Balance – January 1, 2022	309,286	\$ 2,366,038	1,550,094	\$ 155	\$ 146,030,203	\$ 61,523	\$ (88,508,236)	\$ 59,949,683					
Conversion of exchangeable shares to common stock	(2,434)	(18,620)	122	—	18,620	—	—	—					
Settlement of convertible notes	—	—	169,843	17	3,299,983	—	—	—	3,300,000				
Shares withheld for withholding taxes	—	—	(222)	—	(5,615)	—	—	—	(5,615)				
Shares returned in connection with acquisition	—	—	(13,988)	(1)	(939,999)	—	—	—	(940,000)				
Stock-based compensation	—	—	—	—	316,855	—	—	—	316,855				
Issuance of common stock upon vesting of restricted stock units	—	—	2,174	—	—	—	—	—	—				
Liabilities with shares	—	—	(unaudited) ³²	—	45,066	—	—	—	45,066				
Foreign currency translation adjustments	—	—	—	—	—	—	(33,800)	—	(33,800)				
Unrealized gain on convertible notes	—	—	—	—	—	—	101,000	—	101,000				
Net loss	—	—	—	—	—	—	(21,952,893)	—	(21,952,893)				
Balance – March 31, 2022	306,852	\$ 2,347,418	1,708,755	\$ 171	\$ 148,765,113	\$ 128,723	\$ (110,461,129)	\$ 40,780,296					
Conversion of exchangeable shares to common stock	(15,660)	(119,799)	783	—	119,799	—	—	—	59,949,683				
Balance – January 1, 2022	309,286	\$ 2,366,038	1,550,094	\$ 155	\$ 146,030,203	\$ 61,523	\$ (88,508,236)	\$ 59,949,683					
Settlement of convertible notes	—	—	37,584	—	625,496	—	—	—	625,496				
Shares withheld for withholding taxes	(2,434)	(18,620)	122	—	18,620	—	—	—	18,620				
Shares returned in connection with the ATM offering	—	—	169,843	9	3,299,983	1,169	—	—	3,300,000				
Shares withheld for withholding taxes	—	—	(222)	—	(5,615)	444	—	—	(5,615)				
Shares returned in connection with acquisition	—	—	(13,988)	(1)	(939,999)	000	—	—	(940,000)				
Stock-based compensation	—	—	732	—	316,855	4,464	—	—	316,855				
Foreign currency translation adjustments	—	—	—	—	—	10,629	—	—	10,629				
Issuance of common stock upon vesting of restricted stock units	—	—	2,174	—	—	—	163,000	—	163,000				
Net loss	—	—	732	—	45,066	—	—	(29,565,947)	(29,565,947)				
Liabilities with shares	—	—	—	—	—	—	—	—	—				
Balance – June 30, 2022	291,192	\$ 2,227,619	1,841,337	\$ 184	\$ 150,441,933	\$ 302,352	\$ (140,027,076)	\$ 12,945,012					
Foreign currency translation adjustments	—	—	—	—	—	—	(33,800)	—	(33,800)				
Unrealized gain on convertible notes	—	—	—	—	—	—	101,000	—	101,000				
Net loss	—	—	—	—	—	—	—	(21,952,893)	(21,952,893)				
Balance – March 31, 2022	306,852	\$ 2,347,418	1,708,755	\$ 171	\$ 148,765,113	\$ 128,723	\$ (110,461,129)	\$ 40,780,296					
Conversion of exchangeable shares to common stock	(15,660)	(119,799)	783	—	119,799	—	—	—	—				
Settlement of convertible notes	—	—	37,584	4	625,496	—	—	—	625,496				
Shares withheld for withholding taxes	—	—	(337)	—	(7,552)	—	—	—	(7,552)				
Shares returned in connection with the ATM offering program	—	—	90,809	9	761,169	—	—	—	761,178				
Stock-based compensation	—	—	—	—	148,444	—	—	—	148,444				
Issuance of common stock upon vesting of restricted stock units	—	—	3,011	—	25,000	—	—	—	25,000				
Liabilities with shares	—	—	732	—	4,464	—	—	—	4,464				
Foreign currency translation adjustments	—	—	—	—	—	10,629	—	—	10,629				
Unrealized gain on convertible notes	—	—	—	—	—	163,000	—	—	163,000				
Net loss	—	—	—	—	—	—	—	(29,565,947)	(29,565,947)				
Balance – June 30, 2022	291,192	\$ 2,227,619	1,841,337	\$ 184	\$ 150,441,933	\$ 302,352	\$ (140,027,076)	\$ 12,945,012					
Common shares and warrants issued in connection with unit offering	—	—	2,179,13	217	9,178,744	—	—	—	9,178,961				
Stock-based compensation	—	—	—	—	196,124	—	—	—	196,124				
Issuance of common stock upon vesting of restricted stock units	—	—	8,045	1	24,999	—	—	—	25,000				
Foreign currency translation adjustments	—	—	—	—	—	27,676	—	—	27,676				
Unrealized gain on convertible notes	—	—	—	—	—	26,000	—	—	26,000				

Net loss	—	—	—	—	—	—	(2,304,088)	(2,304,088)
Balance - September 30, 2022	<u>291,192</u>	<u>\$ 2,227,619</u>	<u>4,023,294</u>	<u>\$ 402</u>	<u>\$159,841,800</u>	<u>\$ 356,028</u>	<u>\$ (142,331,164)</u>	<u>\$ 20,094,685</u>

The accompanying notes are an integral part of these condensed consolidated financial statements

AKERNA CORP.
Condensed Consolidated Statements of Cash Flows
(unaudited)

	For the Six Months Ended June 30,	
	2023	2022
Cash flows from operating activities		
Net loss	\$ (5,556,579)	\$ (51,518,840)
Adjustments to reconcile net loss to net cash used in operating activities:		
Gain on sale of discontinued operations, net	(212,601)	—
Credit loss expense	(29,010)	112,475
Stock-based compensation expense	217,610	477,681
Impairment of long-lived assets	—	39,600,587
Amortization of deferred contract cost	37,576	205,408
Non-cash interest expense	—	60,500
Depreciation and amortization	594,759	3,976,224
Foreign currency (gain) loss	(22,932)	14,689
Change in fair value of convertible notes	1,048,457	1,727,000
Change in fair value of derivative liability	—	(51,896)
Changes in operating assets and liabilities:		
Accounts receivable, net	167,318	(580,387)
Prepaid expenses and other current assets	343,846	23,530
Accounts payable, accrued expenses and other current liabilities	(218,746)	119,355
Deferred income tax liabilities	—	(206,805)
Deferred revenue	(460,326)	(1,146,966)
Net cash used in operating activities	<u>(4,090,628)</u>	<u>(7,187,445)</u>
Cash flows from investing activities		
Developed software additions	—	(1,737,120)
Fixed asset additions	—	(1,737,120)
Cash returned from business combination working capital settlement	600,000	—
Proceeds from sale of discontinued operations	—	—
Cash flows from operating activities	600,000	—
Net loss	\$ (8,151,516)	\$ (53,822,928)
Adjustments to reconcile net loss to net cash used in operating activities:		
Value of shares withheld related to tax withholdings	(49)	(212,601)
Net cash provided by (used in) investing activities	(49)	(212,601)
Credit loss expense	Proceeds from secured loan	1,000,000
Stock-based compensation expense	Principal payments of convertible notes	(4,917,356)
Impairment of long-lived assets	Proceeds received from the ATM offering program, net	500,000
Amortization of deferred contract cost	—	39,285
Non-cash interest expense	—	761,178
Depreciation and amortization	(3,417,405)	(766,989)
Foreign currency (gain) loss	52,911	(22,139)
Change in fair value of convertible notes	(6,855,122)	(22,139)
Change in fair value of derivative liability	7,877,755	225
Changes in operating assets and liabilities:	13,087,627	4,718
Accounts receivable, net	305,500	(1,354,899)
Prepaid expenses and other current assets	8,183,255	(113,797)
Accounts payable, accrued expenses and other current liabilities	1,328,133	(14,442,526)
Deferred income tax liabilities	—	388,312
Cash and restricted cash - beginning of period	—	(215,228)
Cash and restricted cash of discontinued operations - beginning of period	—	1,356,709
Deferred revenue	\$ 1,328,133	\$ (340,130)
Net cash used in operating activities	\$ 787,182	\$ (5,206,372)
Cash flows from investing activities	\$ 787,182	\$ (5,206,372)
Developed software additions	—	(10,450,906)
Cash paid for interest	—	(19,466)
Fixed asset additions	\$ —	\$ —
Supplemental disclosures of non-cash investing and financing activities:	—	(3,324,029)
Cash returned from business combination working capital settlement	\$ 1,512,101	\$ —
Settlement of convertible notes in common stock	\$ 1,512,101	\$ (27,383)
Proceeds from sale of discontinued operations	255,877	\$ 3,925,500
Conversion of exchangeable shares to common stock	255,877	\$ 400,000
Settlement of other liabilities in common stock	—	\$ 18,419
Stock-based compensation capitalized as software development	—	\$ 49,528
Net cash provided by (used in) investing activities	—	\$ 42,618
Cash flows from financing activities	—	—
Value of shares withheld related to tax withholdings	—	25,000
Capitalized software additions included in accounts payable	—	(49)
Proceeds from unit and pre-funded unit offerings and warrants, net	—	(1,125,299)
Proceeds from secured loan	2,283,806	9,178,961
Termination of contingent consideration obligation in connection with sale of discontinued operations	1,000,000	—
For the Nine Months Ended September 30,	2023	2022

Principal payments of convertible notes of common stock returned in connection with acquisition	—	(4,917,356)	1,000	(1,432,273)
Proceeds received from private placement offering from an acquisition-related working capital settlement	—	500,000	0,000	—
Proceeds received from the ATM offering program, net	—	—	—	761,178
Net cash used in financing activities		(3,417,405)		(8,494,699)
Effect of exchange rate changes on cash and restricted cash		50,099		(35,984)
Net change in cash and restricted cash		(7,973,678)		(4,943,603)
Cash and restricted cash of continuing operations - beginning of period		7,877,755		13,087,627
Cash and restricted cash of discontinued operations - beginning of period		305,500		1,354,899
Cash and restricted cash - beginning of period		8,183,255		14,442,526
Cash and restricted cash of continuing operations - end of period		209,577		9,012,075
Cash and restricted cash of discontinued operations - end of period		—		486,848
Cash and restricted cash - end of period	\$	209,577	\$	9,498,923
 Cash paid for interest	\$	787,187	\$	234,227
Cash paid for income taxes, net of refunds received	\$	—	\$	12,200
 Supplemental disclosures of non-cash investing and financing activities:				
Settlement of convertible notes in common stock	\$	3,012,101	\$	3,925,500
Conversion of exchangeable shares to common stock		277,450		138,419
Settlement of other liabilities in common stock		—		49,530
Stock-based compensation capitalized as software development		—		14,046
Vesting of restricted stock units		—		50,000
Capitalized software additions included in accounts payable		—		32,473
Termination of contingent consideration obligation in connection with sale of discontinued operations		2,283,806		—
Shares of common stock returned in connection with acquisition		—		940,000
Reduction to accrued expenses from an acquisition-related working capital settlement		—		160,000

The accompanying notes are an integral part of these condensed consolidated financial statements

AKERNA CORP.
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Note 1- Description of Business

Akerna Corp., herein referred to as we, us, our, the Company or Akerna was formed upon completion of the mergers between MTech Acquisition Corp. ("MTech") and MJ Freeway, LLC ("MJF") on June 17, 2019 as contemplated by the Merger Agreement dated October 10, 2018, as amended (the "Mergers"). Akerna provides software as a service ("SaaS") solutions within the cannabis industry that enable regulatory compliance and inventory management through our wholly-owned subsidiaries MJF, Ample Organics, Inc., or Ample, Trellis Solutions, Inc., or Trellis, solo sciences, inc., or Solo and Viridian Sciences, Inc., or Viridian. Our proprietary suite of solutions are adaptable for industries in which interfacing with government regulatory agencies for compliance purposes is required, or where the tracking of organic materials from seed or plant to end products is desired. We also develop products intended to assist states in monitoring licensed businesses' compliance with state regulations and to help state-licensed businesses operate in compliance with such law. We provide our commercial software platforms, MJ Platform®, Trellis®, Ample and Viridian to state-licensed businesses, and our regulatory software platform, Leaf Data Systems®, to state government regulatory agencies. Our solutions are considered non-enterprise offerings ("Non-Enterprise") that meet the needs of our small and medium business ("SMB") and government regulatory agency customers and our Viridian solutions are considered enterprise offerings ("Enterprise").

We consult with clients on a wide range of areas to help them successfully maintain compliance with state laws and regulations. We provide project-focused consulting services to clients who are initiating or expanding their cannabis business operations or are interested in data consulting engagements with respect to the legal cannabis industry. Our advisory engagements include service offerings focused on compliance requirement assessments, readiness and best practices, compliance monitoring systems, application processes, inspection readiness, and business plan and compliance reviews. We typically provide our consulting services to clients in emerging markets that are seeking consultation on newly introduced licensing regimes and assistance with the regulatory compliant build-out of operations.

Strategic Shift in Business Strategy

During the fourth quarter of 2022, we committed to a number of significant actions described below that collectively represent a strategic shift in our business strategy for 2023 and beyond.

Exiting the Enterprise Software Business

The development of our Enterprise software business, which began with the acquisitions of Viridian and The NAV People Inc. d.b.a. 365 Cannabis ("365 Cannabis") in 2021, did not achieve a sustainable scale in a timely manner consistent with our original plans. Accordingly, we committed to an effort to market this business unit and on January 11, 2023, we completed the sale of 365 Cannabis to 365 Holdco - LLC (the "Buyers") pursuant to a stock purchase agreement (the "365 SPA") for (i) cash in the amount of \$0.5 million and the (ii) the termination and release of our obligation to the Buyers for contingent consideration in connection with our original acquisition of 365 Cannabis from the Buyers in 2021 (the "Earn-out Obligation"). In accordance with the 365 SPA, we and the Buyers agreed that the value of the Earn-out Obligation was \$2.3 million for purposes of the sale of 365 Cannabis and was reflected as Contingent consideration payable on our condensed consolidated balance sheets as of December 31, 2022. In connection with the sale of 365 Cannabis, we terminated certain employees that were not requested to transfer with the business by the Buyers or whose positions were no longer necessary to support our reduced level of operations. We incurred and paid restructuring charges associated with this action for less than \$0.1 million, \$0.1 million, primarily in the form of severance and related employee benefits, during the first quarter of 2023. The charges were included as a component of Cost of revenues in our condensed consolidated statements of operations.

While we explored similar sale options for Viridian, we were unable to commit to any definitive transaction. Accordingly, we informed Viridian's customers that we do not plan to continue software and support services beyond the date of existing contracts, most of which expired during the first half of 2023. With the sale of 365 Cannabis and our commitment to wind down the operations of Viridian, we have effectively exited the Enterprise software business. Accordingly, we have suspended efforts to seek any new revenue generating opportunities and will only service the existing customers of Viridian in connection with our contractual commitments. We have committed to winding down and terminating this business in advance during the third quarter of 2023 in connection with our exit strategy (see below).

Disposal of Non-Core SMB Software Products and Brands

In addition to the **our** exit from the Enterprise software business, we initiated efforts to explore a sales process for the non-core components and brands of our SMB/Non-Enterprise business unit, including Trellis, a cultivation and compliance software platform, Solo, a seed-to-sale tagging and tracking software platform and Last Call Analytics ("LCA"), a retail analytics platform. On January 31, 2023, we completed the sale of LCA for cash in the amount of **\$0.1 million**. While we pursued sale opportunities for Trellis and Solo, we were ultimately unable to commit to any definitive transactions. Accordingly, we have communicated with the remaining customers of those businesses that we will discontinue software service and support upon the expiration of existing contracts, most of which occurred during the first half of 2023. Similar to Viridian, as discussed above, we have suspended efforts to seek any new revenue generating opportunities and will only service the existing customers of Solo and Trellis in connection with our contractual commitments. We have committed to winding down and terminating these businesses in advance during the third quarter of certain transactions 2023 in connection with our exit strategy (see below).

Exit Strategy

With the completion of the sales of 365 Cannabis and LCA and the commitment to effectively discontinue and wind down the operations and service associated with Viridian, Solo and Trellis, our remaining core SMB and governmental business unit is comprised of MJF and Ample. Concurrent with the actions described above, we entered into letters of intent with two unrelated parties in the fourth quarter of 2022 to (i) explore the sale of our remaining core SMB and governmental business unit and (ii) realize the potential value of our publicly-held holding company through a merger or similar transaction. Collectively, pursuit of these transactions reflects our intention to fully exit the SaaS industry.

On January 27, 2023, we entered into a securities purchase agreement ("MJF-Ample SPA") with POSaBIT Systems Corp ("POSaBIT") to sell MJF and Ample for \$4.0 million in cash. Subsequently, we received a superior offer from Alleaves Inc. ("Alleaves" ("Alleaves")), as described below, which was presented to POSaBIT for an opportunity to match or exceed Alleaves' Alleaves' offer in accordance with the MJF-Ample SPA. POSaBIT ultimately declined to present a counter-offer and on April 5, 2023, we terminated the MJF-Ample SPA. As a result of the termination, Akerna paid POSaBIT a termination fee and reimbursement for expenses of **\$0.2 million** \$0.2 million in June 2023. These costs were included as Other expense, net in our condensed consolidated statements of operations.

On January 27, 2023, we entered into an agreement and plan of merger (the "Merger Agreement") with Gryphon Digital Mining, Inc. Inc. ("Gryphon") and Akerna Merger Co. ("Akerna Merger"). Upon the terms and subject to the satisfaction of the conditions provided in the Merger Agreement, including the approval of the transaction by Akerna's and Gryphon's stockholders, Akerna Merger will be merged with and into Gryphon (the "Merger"), with Gryphon surviving the Merger as a wholly-owned subsidiary of Akerna. Following the closing of the Merger, the former Gryphon and Akerna stockholders immediately before the Merger are expected to own approximately 92.5 percent and 7.5 percent, respectively, of the outstanding capital stock on a fully diluted basis. Upon completion of the Merger, Akerna will change its name to Gryphon Digital Mining, Inc. Inc. The closing of the Merger is subject to customary closing conditions including the required approval of the stockholders of Akerna and Gryphon, the approval of the Nasdaq Capital Market (the "Nasdaq" "Nasdaq Market") of the continued listing of Gryphon after the closing of the Merger and the simultaneous closing of the sale of MJF and Ample(see (see below, the "Sale Transaction"), among others. We and Gryphon may terminate the Merger upon mutual consent and either party may terminate the Merger unilaterally under certain conditions. In the event either party terminates the Merger pursuant to certain conditions, we will be required to pay Gryphon a termination fee of **\$275,000** \$275,000 less any reimbursed expenses. The Merger is expected to be treated by Akerna as a reverse merger, or a change of control, whereby the stockholders of Gryphon will have majority ownership and control of Akerna after the transaction is complete.

On April 28, 2023, we entered into a securities purchase agreement (the "SPA") with MJ Freeway Acquisition Co ("MJ Acquisition" "Acquisition"), an affiliate of Alleaves. Upon the terms and subject to the satisfaction of the conditions described in the SPA, including approval of the transaction by Akerna's stockholders, Akerna will sell MJF and Ample to MJ Acquisition for a purchase price of \$5.0 million, consisting of \$4.0 million in cash at closing and a loan by MJ Acquisition to Akerna in the principal amount of \$1.0 million evidenced by a note and security documents (as described in detail below) with such note to be deemed paid in full upon closing. The purchase price is subject to adjustment at closing of the Sale Transaction attributable to variances from target working capital (as set forth in the SPA) and further adjustment post-closing post- closing upon delivery of a post-closing statement by MJ Acquisition within 75 days after the closing subject to a \$0.5 million cap on any post-closing post- closing working capital adjustments. The closing of the Sale Transaction is subject to customary closing conditions as well as the required approval of the stockholders of Akerna and the closing of the Merger. The obligation of MJ Acquisition to close on the Sale Transaction is also subject to satisfaction of certain additional conditions regarding employee retention and contractual matters associated with MJF's MJF's and Ample's Ample's customers, among others, others. Under the SPA, Akerna and MJ Acquisition have agreed to provide limited indemnification to each other with respect to certain tax matters, in each case capped at a maximum amount of **\$0.5 million** \$0.5 million. We or MJ Acquisition may terminate the SPA upon mutual consent and either party may terminate the SPA unilaterally under certain conditions as described in the SPA. In the event that MJ Acquisition or Akerna terminates the SPA pursuant to certain of the sections set forth above, Akerna will be required to pay MJ Acquisition a termination fee of \$290,000 and reimburse MJ Acquisition for its reasonable fees and expenses up to \$60,000.

On June 14, 2023, the Merger Agreement was amended to add the defined term "Closing Acquiror Share Price" and amend and restate the definition of "Merger Consideration." The term "Closing Acquiror Share Price" means the last reported sale price per share of Akerna Common Stock on Nasdaq on the second business day prior to the closing date of the Merger and the term "Merger Consideration" means the greater of (a) a number of shares of Akerna Common Stock equal to (i) the quotient obtained by dividing (A) Akerna's fully diluted share number, as defined in the Merger Agreement, by (B) 0.075, minus (ii) the Akerna's fully diluted share number minus (iii) the adjusted warrant share reserve number, as defined in the Merger Agreement, and (b) a number of shares of Akerna's Common Stock equal to the quotient obtained by dividing (i) \$115,625,000 by (ii) the Closing Acquiror Share Price. The amendment effectively sets a floor of \$115.6 million for the value attributable to Gryphon in the determination of post-Merger ownership.

Concurrent with the signing and in support of the Sale Transaction and the Merger, we and each of the holders of the 2021 Senior Secured Convertible Notes (the "Senior Convertible Notes") entered into exchange agreements (the "Exchange Agreements") whereby the holders would ultimately convert the principal amounts of each of their note holdings to a level that would represent 19.9 percent of the outstanding shares of our common stock, ~~\$0.0001~~ \$0.0001 par value ("Common Stock") prior to the closing of the Sale Transaction and the Merger. Immediately prior to the stockholder vote required for the closing of those transaction, the remaining Senior Convertible Notes outstanding would be converted into a special class of exchangeable preferred stock to facilitate the required stockholder vote and then be converted into shares of our Common Stock subject to the Merger. For a limited period, the conversion price of the Senior Convertible Notes was lowered to ~~\$1.20~~ \$1.20 per share from ~~\$4.75~~ \$4.75 per share. In accordance with the Exchange Agreements and upon the occurrence of an any additional capital raising transaction, the conversion price would be adjusted accordingly. In connection with an equity offering in June 2023 (see Note 9), the conversion price was further reduced to \$0.50 per share. We anticipate scheduling a meeting of stockholders during the ~~third~~ ~~fourth~~ quarter of 2023 to approve the Merger and the Sale Transaction and we expect these transactions to close shortly thereafter.

Restructuring*First Amendment to Securities Purchase Agreement*

As previously reported, on April 28, 2023, Akerna entered into a securities purchase agreement (the "SPA") with Akerna Canada Ample Exchange Inc. ("Akerna Exchange") and MJ Acquisition Corp. ("MJA"). Upon the terms and subject to the satisfaction of the conditions described in the SPA, including approval of the transaction by Akerna's stockholders, Akerna will sell to MJA (or a subsidiary of MJA) all of the membership interests in MJ Freeway, LLC ("MJF") and Akerna Exchange will sell to MJA all of the outstanding capital stock of Ample Organics Inc. ("Ample") (jointly, such sales, the "Sale Transaction").

On September 28, 2023, Akerna, Akerna Exchange and MJA entered into a first amendment to the SPA (the "Amendment") which amends certain of the terms of the SPA. Principally, the Amendment:

- (i) amends Article I of the SPA to add certain definitions regarding the Amended and Restated Note (as defined below);
- (ii) amends Article I to change the "Outside Date" as defined therein from September 29, 2023 to December 31, 2023;
- (iii) amends Section 2.2 of the SPA to reduce the amount of cash to be paid at closing from \$4 million to \$2 million;
- (iv) amends Section 5.14 of the SPA to add to the items of business in relation to which Akerna will seek stockholder approval at a special meeting of the stockholders the issuance of shares of common stock of Akerna to MJA under the Amended and Restated Note;
- (v) adds a new Section 5.19 which provides that prior to closing under the SPA, MJA will work in good faith on a best efforts basis across multiple interested parties on behalf of and with the express approval of Akerna to secure for Akerna the highest purchase price possible for the shares of Ample. Akerna shall cause the proceeds from such sale to be included in the assets of MJF effective as of the closing. Notwithstanding the foregoing, in the event that the shares of Ample are sold to a third-party for a net purchase price above \$700,000, Akerna shall be entitled to retain all net proceeds in excess of \$700,000;
- (vi) provides that, within 3 business days of the Amendment, MJA will loan Akerna an additional \$500,000 to fund Akerna's working capital requirements; and
- (vii) provides that concurrently with the funding of the additional \$500,000 loan to Akerna, Akerna will issue and amend and restated convertible secured promissory note ("Amended and Restated Note") to MJA which amends and restates the Secured Promissory Note dated April 28, 2023 by and between Akerna and MJA (the "Original Note") to (A) increase the principal amount of the Original Note from \$1,000,000 to \$1,500,000, (B) provide for the forfeiture by MJA of the accrued and unpaid interest at the consummation of the transaction under the SPA and (C) provide that contemporaneous with and immediately prior to the consummation of the transactions under the SPA provide that contemporaneous with and immediately prior to the consummation of the transactions under the SPA, the principal amount of the shall convert into such quantity of shares of common stock of the Company as equals (1) \$1,500,000, multiplied by (2) the 5-day volume weighted average price of the common stock of the Company as quoted on The Nasdaq Capital Market for the 5 trading days immediately preceding the date of the consummation of the transactions under the SPA; provided however, that in no case shall Akerna be required to issue to MJA such number of shares of common stock as would in the aggregate with all shares issued pursuant to the SPA and/or held or controlled by MJA exceed 19.99% of the number of issued and outstanding shares of common stock of the Seller on the date hereof without first obtaining the approval of stockholders of Akerna as required pursuant to the rules of the Nasdaq Stock Exchange.

Amended and Restated Convertible Secured Promissory Note

In relation to the first amendment to the Securities Purchase Agreement dated September 28, 2023 by and between Akerna, Akerna Exchange and MJA, Akerna issued an amended and restated convertible secured promissory note ("Amended and Restated Note") on October 11, 2023 to MJA which amends and restates the Secured Promissory Note dated April 28, 2023 by and between Akerna and MJA (the 'Original Note'), whereby Akerna promises to pay to the order of MJA or its registered assigns the amount of \$1,500,000. The Amended and Restated Note amended the Original Note to:

- (i) increase the principal amount of the Original Note from \$1,000,000 to \$1,500,000;
- (ii) provide for the forfeiture by MJA of the accrued and unpaid interest at the consummation of the transaction under the SPA; and
- (iii) provide that contemporaneous with and immediately prior to the consummation of the transactions under the SPA provide that contemporaneous with and immediately prior to the consummation of the transactions under the SPA, the principal amount of the shall convert into such quantity of shares of common stock of the Company as equals (1) \$1,500,000, multiplied by (2) the 5-day volume weighted average price of the common stock of the Company as quoted on The Nasdaq Capital Market for the 5 trading days immediately preceding the date of the consummation of the transactions under the SPA; provided however, that in no case shall Akerna be required to issue to MJA such number of shares of common stock as would in the aggregate with all shares issued pursuant to the SPA and/or held or controlled by MJA exceed 19.99% of the number of issued and outstanding shares of common stock of the Seller on the date hereof without first obtaining the approval of stockholders of Akerna as required pursuant to the rules of the Nasdaq Stock Exchange.

Except as set forth above, no other amendments, revisions or additions were made to the Original Note and all terms, conditions, covenants, representations and warranties contained in the Original Note shall remain in full force and effect.

Amended and Restated Security Agreement

Pursuant to the Amended and Restated Note, Akerna's obligations under the Amended and Restated Note are to be secured pursuant to an Amended and Restated Security and Pledge Agreement entered into by and among Akerna, MJA and the other parties thereto dated October 11, 2023 (the "Amended and Restated Security Agreement"). The Amended and Restated Security Agreement amended and restated the Security Agreement entered into by and among Akerna, MJA and other parties thereto dated April 28, 2023 (the "Original Security Agreement") to reflect the entry into the Amended and Restated Note and change reference therein from the Original Note to the Amended and Restated Note.

Except as set forth above, no other amendments, revisions or additions were made to the Original Security Agreement and all terms, conditions, covenants, representations and warranties contained in the Original Security Agreement shall remain in full force and effect.

Amended and Restated Guaranty

In connection to the Amended and Restated Note, certain subsidiaries of Akerna entered into an amended and restated guaranty agreement with MJA on October 11, 2023 (the "Amended and Restated Guaranty Agreement") under which they will guarantee the obligations of the Company under the Amended and Restated Note.

Waiver

In connection to the Amended and Restated Note, the Amended and Restated Security Agreement, and the Amended and Restated Guaranty Agreement (collectively, "Amended and Restated New Note Transaction Documents") and solely to permit Akerna to issue the Amended and Restated Note and execute and perform its obligations under the Amended and Restated New Note Transaction Documents and the Amended and Restated Subordination Agreement (as defined below), on October 11, 2023, each of the holders (each, a "Holder") of Akerna's senior secured convertible notes (the "2021 Notes") issued pursuant to a Securities Purchase Agreement dated October 5, 2021 ("2021 SPA") agreed to waive the prohibition on issuing indebtedness other than Permitted Indebtedness (as defined in the 2021 Notes) pursuant to Section 14(b) of the 2021 Notes and the prohibition permitting Liens (as defined in the 2021 Notes) to exist other than Permitted Liens (as defined in the 2021 Notes) pursuant to Section 14(c) of the 2021 Notes and Section 5(g)(v) of the 2021 SPA (the "Waiver").

Amended and Restated Subordination and Intercreditor Agreement

In connection to the Amended and Restated New Note Transaction Documents, MJA, Akerna, and HT Investments MA LLC (the "Senior Agent", together with the Holders, the "Senior Creditors"), as collateral agent under the 2021 SPA, each on behalf of the respective Holders, entered into an amended and restated subordination and intercreditor agreement dated October 11, 2023 (the "Amended and Restated Subordination Agreement"), whereby the parties agreed that the payment of any and all obligations, liabilities and indebtedness of every nature of Akerna, its applicable subsidiary and/or affiliates from time to time owed to MJA under Amended and Restated Subordinated Debt Documents (as defined in the Amended and Restated Subordination Agreement) will be subordinate and subject in right and time of payment, to the prior payment in full of all obligations, liabilities and indebtedness of every nature of Akerna, its applicable subsidiary and/or affiliates from time to time owed to any Senior Creditor under the Senior Debt Documents (as defined in the Amended and Restated Subordination Agreement).

Restructuring

In May 2022, we implemented a corporate restructuring initiative (the "Restructuring") that resulted in a charge of \$0.5 million associated with a reduction of our workforce by 59 employees, or approximately 33 percent of our headcount at that time. The charge associated with the Restructuring, all of which was settled in cash during the second quarter of 2022, was comprised primarily of severance benefits and related costs and was fully attributable to our continuing operations. Of the total amount incurred, \$0.3 million was included in Sales and marketing costs, approximately \$0.2 million was included in Product development costs and less than \$0.1 million was included in each of Cost of revenue and General and administrative expenses in our condensed consolidated statements of operations, respectively.

Financial Reporting and Classification

As a result of the corporate actions described above, 365 Cannabis and LCA (together, the "Discontinued Group") met the criteria to be considered "held for sale" as that term is defined in accounting principles generally accepted in the United States ("GAAP"). Accordingly, the assets and liabilities of these entities are classified and reflected on our condensed consolidated balance sheets as "held for sale" as of December 31, 2022 and their results of operations and the effect of their sales have been classified as "discontinued operations" in the condensed consolidated statements of operations for the three and **six** nine months ended **June 30, 2023** **September 30, 2023** and 2022, respectively. Certain financial disclosures including major components of the assets and liabilities and results of operations of the Discontinued Group are provided in Note 12. Our core SMB and governmental business unit (MJF and Ample), the businesses for which we have committed to terminate operations (Viridian, Solo and Trellis) and our publicly-held parent holding company (Akerna Corp.) comprise our continuing operations. Collectively, these entities are presented as continuing operations for all periods presented herein and until such time that stockholder approval is received for the Sale Transaction and the Merger.

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies

Going Concern and Management's Liquidity Plans

In accordance with the Financial Accounting Standards Board's ("FASB") standard on going concern, Accounting Standard Update ("ASU") No. **2014-15, 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as Going Concern ("ASU 2014-15" 2014-15")**, we assess going concern uncertainty in our condensed consolidated financial statements to determine if we have sufficient cash, cash equivalents and working capital on hand and any available borrowings on loans, to operate for a period of at least one year from the date the condensed consolidated financial statements are issued. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and our ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions regarding implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable that such implementations can be achieved and we have the proper authority to execute them within one year from the date the condensed consolidated financial statements are issued.

The accompanying consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. However, since our inception in 2019 we have incurred recurring losses from operations, used cash from operating activities, and relied on capital raising transactions to continue ongoing operations. As of **June 30, 2023** **September 30, 2023**, we had a working capital deficit of **\$9.7 million** **\$11.2 million** with **\$1.3 million** **\$0.2 million** in cash available to fund future operations including **\$0.5 million** in cash that was classified as "restricted" as of **June 30, 2023**. The restrictions on those accounts were eliminated in July 2023 and the amounts became fully available for our use as working capital. We anticipate continuing to generate losses from operations and using cash from operating activities for the foreseeable future, although at lower than historical levels as a result of Restructuring during the second quarter of 2022 and the curtailment of activities associated with our discontinued operations as well as those business that we plan to terminate, have terminated. Furthermore, on March 22 and March 23, 2023, respectively, we received notices (the "Notices") from The Nasdaq Stock Market LLC (the "Nasdaq") indicating that (i) the bid price of the Company's Common Stock is not currently in compliance with the requirement to maintain a minimum bid price of **\$1.00** per share (the "Bid Price Notice") and (ii) the Company's stockholders' equity is below the minimum listing standard requirement of \$2.5 million for continued listing on the Nasdaq (the "Stockholders Equity Notice"). The Notices have no immediate effect on the continued listing status of our Common Stock on the Nasdaq, and, therefore, our listing remains fully effective. We are provided a compliance period of 180 calendar days from the date of the Bid Price Notice, or until September 18, 2023, to regain compliance with the minimum closing bid requirement. Regarding the Stockholders Equity Notice, we submitted the required compliance plan to the listings staff of the Nasdaq on May 8, 2023 which was conditioned upon the successful completion of the Merger. On June 15, 2023, we received a letter from Nasdaq granting an extension through September 19, 2023 to complete the Merger. On September 19, 2023, the Company received a determination letter (the "Determination Letter") from the Staff stating that it had not regained compliance with the minimum bid price requirement or the minimum listing standard requirement of \$2.5 million and is not eligible for an additional 180-day period to regain compliance. Further, the Determination Letter indicates that unless the Company requests an appeal of this determination the trading of the extension include: (i) receiving approval Company's common stock will be suspended at the opening of business on September 28, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from Nasdaq to list the post-Merger entity, (ii) completion of the Merger transaction listing and (iii) meeting all of the initial and continued listing requirements for the registration on The Nasdaq Capital Market. Collectively, these factors raise substantial doubt regarding our ability The Company had a deadline to continue as appeal the Staff's determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, no later than 4:00 pm Eastern Time on September 26, 2023. The Company successfully submitted a going concern hearing request on September 25, 2023 and received a hearing date of November 9, 2023. This Hearing will stay any delisting or suspension action by the Staff pending the issuance of the Panel's decision. The Company's common stock will remain listed on Nasdaq, pending the outcome of the Hearing. There can be no assurance that the Panel will grant the Company's request for continued listing, however on November 2, 2023 the twelve months Company received a document from the date our condensed consolidated financial statements have been issued. Nasdaq Staff indicating, based on their review it appears that the post-transaction (referring to the Akerna Merger) entity will demonstrate compliance with the initial listing requirements, only in the event that the transaction successfully closes.

As described in Note 1, we have committed to the Sale Transaction to complete our intended exit from the SaaS industry and to the Merger as the most favorable strategic alternative for our stockholders. There can be no assurance that we will be successful in executing and completing the Sale Transaction and the Merger and obtaining sufficient funding, if necessary, on terms acceptable to us to fund continuing operations through the anticipated closing of the aforementioned transactions, if at all. Our ability to continue as a going concern is dependent upon our ability to successfully execute the aforementioned transactions. Despite the comprehensive scope of our collective plans, the inherent risks associated with their successful execution are not sufficient to overcome substantial doubt about our ability to continue as a going concern for one year from the date of issuance of our consolidated financial statements. Accordingly, if we are unable to execute our plans within the timeframe described above, we may have to reduce or otherwise curtail our continuing operations which could significantly and adversely affect our results of operations or we may determine to dissolve and liquidate our assets. If we fail to meet the financial covenants of the Senior Convertible Notes and cannot obtain a waiver from such provisions or otherwise come to an agreement with the Holders of the Senior Convertible Notes, such Holders may declare a default on the debt which could subject our assets to seizure and sale, negatively impacting our business.

The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and with the instructions to the Quarterly Report on Form 10-Q and Article 8 of Regulation S-X for interim financial information. Accordingly, these financial statements do not include all of the information normally required by GAAP or Securities and Exchange Commission rules and regulations for complete financial statements. In management's opinion, these condensed consolidated financial statements include all adjustments, consisting of normal recurring items, considered necessary for the fair presentation of the results of operations for the interim periods presented. The operating results for the three and **six** **nine** months ended **June 30, 2023** **September 30, 2023** are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023.

The condensed consolidated balance sheet as of December 31, 2022, has been derived from our audited financial statements at that date but does not include all disclosures and financial information required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with our consolidated financial statements and notes thereto for the period ended December 31, 2022, which were included in our report on Form 10-K filed on **March 20, 2023** **March 20, 2023**.

Principles of Consolidation

Our accompanying condensed consolidated financial statements include the accounts of Akerna and our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts included in the condensed consolidated financial statements and accompanying notes thereto. Our most significant estimates and assumptions are related to the valuation of acquisition-related assets and liabilities, capitalization of internal costs associated with software development, fair value measurements, credit loss reserves, impairment assessments, loss contingencies, valuation allowance associated with deferred tax assets, stock based compensation expense, and useful lives of long-lived intangible assets. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Accordingly, actual results could differ from those estimates.

Accounts Receivable, Net

We maintain an allowance for credit losses equal to the estimated uncollectible amounts based on historical information, current conditions, and reasonable and supportable forecasts. Receivables are written-off and charged against the recorded allowance when we have exhausted collection efforts without success. The allowance for credit losses was less than \$0.1 million and \$0.4 million as of June 30, 2023 September 30, 2023 and December 31, 2022, respectively. respectively.

Concentrations of Credit Risk

We grant credit in the normal course of business to customers in the United States and Canada. We periodically perform credit analysis and monitor the financial condition of our customers to reduce credit risk.

During the sixnine months ended June 30, 2023September 30, 2023 and 2022, two government clients accounted for 27 percent and 26 percent of total revenues, respectively. As of June 30, 2023, September 30, 2023, and December 31, 2022 two government clients accounted for 10 percentone and 33 percent, respectively of net accounts receivable.

Warrants

Warrants

We evaluate warrants that we may issue from time to time under a two-step process provided in GAAP. The first step is intended to distinguish liabilities from equity. Warrants that could require cash settlement are generally classified as liabilities. For warrants that are considered outside of the scope of liability classification, a second step evaluates warrants as either a derivative subject to derivative accounting and disclosures or as equity instruments based upon the specific terms of the underlying warrant agreement and certain other factors associated with the our capital structure. Warrants that are indexed to the Company's Company's Common Stock while we meet certain other conditions with respect to our capital structure, including the ability to satisfy the warrant settlement obligations with a sufficient number of registered shares, do not qualify as derivatives and are classified as components of equity. Certain of the warrants sold by MTech in its initial public offering that were converted to Akerna warrants in connection with the Mergers (the "Private Warrants") are not indexed to our common stock in the manner contemplated as described herein. As a result, the Private Warrants are precluded from equity classification and are recorded as derivative liabilities. At the end of each reporting period, changes in fair value during the period are recognized within the condensed consolidated statements of operations. We will continue to adjust this derivative liability for changes in the fair value until the earlier of (a) the exercise or expiration of the Private Warrants or (b) the redemption of the Private Warrants, at which time they will be reclassified to Additional paid-in capital. As of June 30, 2023 September 30, 2023, all of our other outstanding warrants, including certain other MTech warrants that were converted to Akerna warrants upon our formation (the "2019 Public Warrants"), are classified within stockholders' equity.

Segment Reporting

We operate our business as one operating segment. Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker ("CODM"("CODM"), our Chief Executive Officer, in deciding how to allocate resources and assess performance. Our CODM allocates resources and assesses performance based upon discrete financial information at the consolidated level.

In the following table, we disclose the combined gross balance of our fixed assets, capitalized software, and intangible assets by geographical location:

	As of June 30, 2023	As of December 31, 2022	As of September 30, 2023		As of December 31, 2022	
			2023	2022	31, 2022	2022
Long-lived assets:						
United States	\$ 33,604	\$ 48,879	\$ 27,425	\$ 48,879		
Canada	3,972,605	4,527,581	2,909,966	4,527,581		
Total	\$ 4,006,209	\$ 4,576,460	\$ 2,937,391	\$ 4,576,460		

Adoption of Recent Accounting Pronouncements

The FASB issued ASU No. **2016-13, 2016-13, Measurement of Credit Losses on Financial Instruments** ("ASU 2016-13" 2016-13) which introduced a new model for recognizing credit losses on financial instruments based on estimated current expected credit losses, or CECL. ASU 2016-13 2016-13 requires an entity to estimate CECL on trade receivables at inception, based on historical information, current conditions, and reasonable and supportable forecasts. We adopted ASU 2016-13, 2016-13, and subsequent amendments on January 1, 2023. The impact of the adoption of ASU 2016-13 2016-13 on our condensed consolidated financial statements was not material.

Subsequent Events

Management has evaluated all of our activities through the issuance date of our condensed consolidated financial statements and has concluded that, with the exception of incremental issuances of Common Stock as described below, no other subsequent events have occurred that would require recognition in our condensed consolidated financial statements or disclosure in the notes thereto. From July 1, 2023 October 1, 2023 through August 11, 2023 November 14, 2023, a total of \$0.4 million \$0.125 million of principal under the Senior Convertible Notes was converted into 800,000 shares 250,000 shares of our Common Stock at a conversion price of \$0.50 per share. In addition, a total of 2,587 shares of Common Stock were issued to employees in connection with the vesting of certain restricted stock units and 141 shares of Common Stock were issued in connection with the conversion of [2,820] exchangeable shares.

Note 3 – Revenue and Contracts with Customers

Disaggregation

Disaggregation of Revenue

We derive the majority of our revenue from subscription fees paid for access to and usage of our SaaS solutions for a specified period of time, typically one to three years. In addition to subscription fees, contracts with customers may include implementation fees for launch assistance and training. Fixed subscription and implementation fees are billed in advance of the subscription term and are due in accordance with contract terms, which generally provide for payment within 30 days. Our contractual arrangements include performance, termination and cancellation provisions, but do not provide for refunds. Customers do not have the contractual right to take possession of our software at any time. The following tables summarizes our revenue disaggregation by customer type and geographic region for the following periods:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
Government	\$ 635,822	\$ 829,292	\$ 1,315,391	\$ 1,997,622
Non-government	<u>Three Months Ended June 30, 2023</u> \$ 2,287,868	<u>Three Months Ended June 30, 2022</u> \$ 3,489,676	<u>Six Months Ended June 30, 2023</u> \$ 4,890,557	<u>Six Months Ended June 30, 2022</u> \$ 7,347,134
United States	<u>Three Months Ended September 30, 2023</u> \$ 627,803	<u>Three Months Ended September 30, 2022</u> \$ 638,641	<u>Three Months Ended September 30, 2023</u> \$ 1,943,195	<u>Three Months Ended September 30, 2022</u> \$ 2,636,263
Canada	<u>Three Months Ended September 30, 2023</u> \$ 1,454,750	<u>Three Months Ended September 30, 2022</u> \$ 2,425,738	<u>Three Months Ended September 30, 2023</u> \$ 5,029,914	<u>Three Months Ended September 30, 2022</u> \$ 8,162,872
Government	<u>Three Months Ended September 30, 2023</u> \$ 2,082,553	<u>Three Months Ended September 30, 2022</u> \$ 3,064,379	<u>Three Months Ended September 30, 2023</u> \$ 6,973,109	<u>Three Months Ended September 30, 2022</u> \$ 10,799,135
Contracts with Multiple Performance Obligations				
	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
United States	\$ 1,595,271	\$ 2,295,362	\$ 5,305,703	\$ 267,468
Canada	<u>487,282</u>	<u>769,017</u>	<u>1,667,406</u>	<u>2,531,667</u>
	<u>Three Months Ended September 30, 2023</u> \$ 2,082,553	<u>Three Months Ended September 30, 2022</u> \$ 3,064,379	<u>Three Months Ended September 30, 2023</u> \$ 6,973,109	<u>Three Months Ended September 30, 2022</u> \$ 10,799,135

Customers may elect to purchase a subscription to multiple modules, multiple modules with multiple service levels, or, for certain of the Company's solutions. We evaluate such contracts to determine whether the services to be provided are distinct and accordingly should be accounted for as separate performance obligations. If we determine that a contract has multiple performance obligations, the transaction price, which is the total price of the contract, is allocated to each performance obligation based on a relative standalone selling price method. We estimate standalone selling price based on observable prices in past transactions for which the product offering subject to the performance obligation has been sold separately. As the performance obligations are satisfied, revenue is recognized as discussed above in the product descriptions.

Transaction Price Allocated to Future Performance Obligation

GAAP provides certain practical expedients that limit the required disclosure of the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied. As many of the contracts the Company has entered into with customers are for a twelve-month subscription term, a significant portion of performance obligations that have not yet been satisfied as of June 30, 2023 September 30, 2023 are part of a contract that has an original expected duration of one year or less. For contracts with an original expected duration of greater than one year, for which the practical expedient does not apply, the aggregate transaction price allocated to the unsatisfied performance obligations was \$2.8 million \$3.0 million as of June 30, 2023 September 30, 2023, of which \$2.7 million \$2.9 million is expected to be recognized as revenue over the next twelve months.

Deferred Revenue

Deferred revenue represents the unearned portion of subscription and implementation fees. Deferred revenue is recorded when cash payments are received in advance of performance. Deferred amounts are generally recognized within one to three years. Deferred revenue is included in the accompanying consolidated balance sheets under current liabilities, net of any long-term portion that is included in noncurrent liabilities. The following table summarizes deferred revenue activity for the six nine months ended **June 30, 2023** **September 30, 2023**:

	As of		Revenue recognized	As of
	December 31, 2022	Net additions		
Deferred revenue	\$ 730,573	4,719,118	(4,979,817)	\$ 313,100
Deferred revenue	\$ 730,573	4,719,118	(4,979,817)	\$ 313,100

Of the \$4.8 million \$5.0 million of revenue recognized in the six nine months ended **June 30, 2023** **September 30, 2023**, \$0.5 million was \$0.7 million was included in deferred revenue at December 31, 2022.

Costs to Obtain Contracts

We capitalize sales commissions that are directly related to obtaining customer contracts and that would not have been incurred if the contract had not been obtained. These costs are included in the accompanying consolidated balance sheets and are classified as a component of Prepaid expenses and other current assets. Deferred contract costs are amortized to sales and marketing expense over the expected period of benefit, which we have determined to be one to three years based on the estimated customer relationship period. The following table summarizes deferred contract cost activity for the six nine months ended **June 30, 2023** **September 30, 2023**:

	As of		Amortized costs	As of
	December 31, 2022	Additions		
Deferred contract costs	\$ 36,465	—	(36,465)	—
Note 4 - Intangible Assets, net and Goodwill				
Finite-lived Intangible Assets				
Deferred contract costs	\$ 36,465	—	(34,756)	\$ 1,709

All of our finite-lived intangible assets, including capitalized software, as of **June 30, 2023** **September 30, 2023** and December 31, 2022 are attributable to Ample. We did not capitalize any software development costs during the three and six nine months ended **June 30, 2023** **September 30, 2023**; however, we capitalized \$0.7 million \$0.3 million and \$2.2 million \$2.5 million during the three and six nine months ended **June 30, 2022** **September 30, 2022**, respectively.

We performed a two step impairment test for the asset groups that had indicators of impairment during the six nine months ended **June 30, 2023** **September 30, 2023** and 2022 and while we did not record any impairments during the 2023 periods, we recorded impairments of intangible assets of \$2.2 million and capitalized software of \$1.0 million during the three and six nine months ended **June 30, 2022** **September 30, 2022**. Each of these impairments were attributable to the Solo platform.

Goodwill

Non-Enterprise Reporting Unit

For the three and six nine months ended **June 30, 2023** **September 30, 2023**, no \$0.9M impairment to goodwill was recorded for our Non-Enterprise business unit as the fair value exceeded did not exceed the carrying value as of **June 30, 2023** **September 30, 2023** due to declines in market valuation during the current quarter. All of the goodwill as of **June 30, 2023** **September 30, 2023** and December 31, 2022 is attributable to Ample. For the three and six nine months ended **June 30, 2022** **September 30, 2022**, due primarily to declines in market valuation from December 31, 2021, we recorded impairment charges of \$8.0 million \$0 million and \$23.5 million, respectively, of which \$2.7 million and \$10.7 million was attributable to Ample, \$4.9 million and \$11.2 million was attributable to Solo and \$0.4 million and \$1.6 million was attributable to Trellis. The remaining goodwill associated with Solo and Trellis was fully impaired in the second half of 2022.

Enterprise Reporting Unit

For the three and six nine months ended **June 30, 2023** **September 30, 2023**, no, no impairments to goodwill were recorded for our Enterprise business unit as there was no goodwill asset present as of **June 30, 2023** **September 30, 2023**. For the three and six nine months ended **June 30, 2022** **September 30, 2022**, we recorded an impairment of goodwill of \$3.9 million attributable to Viridian due primarily to declines in market valuation from December 31, 2021. All of the remaining goodwill associated with Viridian was fully impaired in the second half of 2022.

Note 5 – Long Term Debt

Long-term debt consisted of the following as of the dates presented:

	<u>June 30, 2023</u>	<u>December 31, 2022</u>
Total long-term debt	<u>\$ 10,265,000</u>	<u>\$ 14,607,000</u>
Less: Current portion	<u>(7,770,543)</u>	<u>(13,200,000)</u>
Noncurrent portion	<u>\$ 2,494,457</u>	<u>\$ 1,407,000</u>
Total long-term debt	<u>2023</u>	<u>2022</u>
Less: Current portion	<u>\$ 7,733,271</u>	<u>\$ 14,607,000</u>
Noncurrent portion	<u>(7,733,271)</u>	<u>(13,200,000)</u>
	<u>—</u>	<u>\$ 1,407,000</u>

Senior Convertible Notes

In October 2021, we entered into a Securities Purchase Agreement dated October 5, 2021 ("2021 SPA") resulting in the issuance of the Senior Convertible Notes to two institutional investors in a private placement transaction. The Senior Convertible Notes were issued for an aggregate principal amount of \$20.0 million for \$18.0 million reflecting an original issue discount of 10 percent or \$2.0 million. The net proceeds from the issuance of the Senior Convertible Notes were used to payoff and retire convertible notes that were issued in 2020 and fund acquisitions and continued investment in our technology infrastructure. The Senior Convertible Notes rank senior to all of our other and future indebtedness. The Senior Convertible Notes mature on October 4, 2024 and can be repaid in shares of Common Stock or cash. The Senior Convertible Notes are convertible into shares of Common Stock of Akerna at a conversion price of \$4.75 per share effective October 4, 2022 which represents an adjustment, as required by the 2021 SPA, from \$6.21 per share as a result of the offering of convertible preferred stock on that date. The Senior Convertible Notes are to be repaid in monthly installments.

In connection with the 2021 SPA and the Senior Convertible Notes, we and certain of our subsidiaries entered into an amended Security and Pledge Agreement (the "Security and Pledge Agreement") with the lead investor, in its capacity as collateral agent (in such capacity, the "Collateral Agent") for all holders of the Senior Convertible Notes. The Security and Pledge Agreement creates a first priority security interest in all of the personal property of the Company and certain of its subsidiaries of every kind and description, tangible or intangible, whether currently owned and existing or created or acquired in the future (the "Collateral").

Upon the occurrence of an "Event of Default" under the Security and Pledge Agreement, the Collateral Agent will have certain rights under the Security and Pledge Agreement including taking control of the Collateral and, in certain circumstances, selling the Collateral to cover obligations owed to the holders of the Senior Convertible Notes pursuant to its terms. An "Event of Default" under the Security and Pledge Agreement means (i) any defined event of default under any one or more of the transaction documents (including the Senior Convertible Notes), in each instance, after giving effect to any notice, grace, or cure periods provided for in the applicable document, (ii) the failure by us to pay any amounts when due under the Senior Convertible Notes or any other transaction document, or (iii) the breach of any representation, warranty or covenant by the Company under the Security and Pledge Agreement.

In connection with the occurrence of an event of default, the holders of the Senior Convertible Notes will be entitled to convert all or any portion of the Senior Convertible Notes at an alternate conversion price equal to the lower of (i) the conversion price then in effect, or (ii) 80% of the lower of (x) the volume-weighted average price ("VWAP") of the Common Stock as of the trading day immediately preceding the applicable date of determination, or (y) the quotient of (A) the sum of the VWAP of Common Stock for each of the two trading days with the lowest VWAP of the Common Stock during the ten consecutive trading day period ending and including the trading day immediately prior to the applicable date of determination, divided by (B) two, but not less than \$10.80 per share.

In connection with the Exchange Agreements that were entered into in January 2023, the conversion price of the Senior Convertible Notes was lowered to \$1.20 per share from \$4.75 per share through June 14, 2023 at which time it was further reduced to \$0.50 per share for a limited period due to the offering of common shares in connection with private placement transaction (see Note 9). During the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, the holders of the Senior Convertible Notes converted a total of **\$1.5 million** **\$3.0 million** of principal for **1,394,251** **4,394,251** shares of Common Stock at the lowered prices.

Method of Accounting and Activity During the Periods

Upon the date that they were issued, we made an irrevocable election to apply the fair value option to account for the Senior Convertible Notes. Disclosures, including the assumptions used to determine the fair value of the Senior Convertible Notes, are provided in Note 10.

During the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, we made **\$6.4 million** **\$7.9 million** in principal payments on the Senior Convertible Notes, of which \$4.9 million was settled in cash and the remaining **\$1.5 million** **\$3.0 million** was settled in Common Stock. During the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, the fair value of the Senior Convertible Notes increased by **\$1.1 million** **\$0.9 million**. Of the adjustment, an increase of less than \$0.1 million resulted from **instrument-specific** **instrument-specific** credit risk and was recognized as other comprehensive loss and accumulated in equity and an increase of **\$1.1 million** **\$0.9 million** was recognized in our consolidated statement of operations as a change in fair value of convertible notes. As of **June 30, 2023** **September 30, 2023**, the fair value of the Senior Convertible Notes on our consolidated balance sheet was **\$9.3 million** **\$7.6 million**. During the **six** **nine** months ended **June 30, 2022** **September 30, 2022**, we made **\$5.4 million** in principal payments on the Senior Convertible Notes, of which \$1.5 million was settled in cash and the remaining \$3.9 million was settled in Common Stock. During the **six** **nine** months ended **June 30, 2022** **September 30, 2022**, the fair value of the Senior Convertible Notes increased by **\$1.4 million** **\$2.5 million**. Of the adjustment, a decrease of \$0.3 million resulted from instrument-specific credit risk and was recognized as other comprehensive income and accumulated in equity and an increase of **\$1.7 million** **\$2.8 million** was recognized in our consolidated statement of operations as a change in fair value of convertible notes.

Secured Note and Ancillary Agreements

On May 3, 2023, we received proceeds from a loan in the amount of **\$1.0 million** **\$1.0 million** from MJ Acquisition in connection with the Sale Transaction. Accordingly, we and MJ Acquisition entered into a **\$1.0 million** **\$1.0 million** secured promissory note (the "MJA Note"). The MJA Note bears simple interest at the rate of ten percent (10%) (10%) per annum from the date of issuance until repayment of the MJA Note which will be due and payable on April 28, 2024, or, upon completion of the Sale Transaction, in which case the MJA Note shall be deemed paid in full. Akerna's obligations under the MJA Note have been secured pursuant to a Security and Pledge Agreement (the "Security Agreement"). The Security Agreement creates a security interest in all of the personal property of Akerna and certain of its subsidiaries. In addition, certain subsidiaries of Akerna entered into a guaranty agreement with MJ Acquisition (the "Guaranty Agreement") under which they will guarantee the obligations of the Company under the Security Agreement and the MJA Note.

On September 28, 2023 Akerna, Akerna Exchange and MJA entered into a first amendment to the SPA (the "Amendment") which amends certain of the terms of the SPA. Principally, the Amendment amends the "Outside Date" as defined therein from September 29, 2023 to December 31, 2023; amends the SPA to reduce the amount of cash to be paid at closing from \$4 million to \$2 million; amends the SPA to add to the items of business in relation to which Akerna will seek stockholder approval at a special meeting of the stockholders the issuance of shares of common stock of Akerna to MJA under the Amended and Restated Note; adds a new Section which provides that prior to closing under the SPA, MJA will work in good faith on a best efforts basis across multiple interested parties on behalf of and with the express approval of Akerna to secure for Akerna the highest purchase price possible for the shares of Ample. Akerna shall cause the proceeds from such sale to be included in the assets of MJF effective as of the closing. Notwithstanding the foregoing, in the event that the shares of Ample are sold to a third-party for a net purchase price above \$700,000, Akerna shall be entitled to retain all net proceeds in excess of \$700,000; provides that, within 3 business days of the Amendment, MJA will loan Akerna an additional \$500,000 to fund Akerna's working capital requirements; and provides that concurrently with the funding of the additional \$500,000 loan to Akerna, Akerna will issue and amend and restated convertible secured promissory note ("Amended and Restated Note") to MJA which amends and restates the Secured Promissory Note dated April 28, 2023 by and between Akerna and MJA (the "Original Note") to (A) increase the principal amount of the Original Note from \$1,000,000 to \$1,500,000, (B) provide for the forfeiture by MJA of the accrued and unpaid interest at the consummation of the transaction under the SPA and (C) provide that contemporaneous with and immediately prior to the consummation of the transactions under the SPA provide that contemporaneous with and immediately prior to the consummation of the transactions under the SPA, the principal amount of the shall convert into such quantity of shares of common stock of the Company as equals (1) \$1,500,000, multiplied by (2) the 5-day volume weighted average price of the common stock of the Company as quoted on The Nasdaq Capital Market for the 5 trading days immediately preceding the date of the consummation of the transactions under the SPA; provided however, that in no case shall Akerna be required to issue to MJA such number of shares of common stock as would in the aggregate with all shares issued pursuant to the SPA and/or held or controlled by MJA exceed 19.99% of the number of issued and outstanding shares of common stock of the Seller on the date hereof without first obtaining the approval of stockholders of Akerna as required pursuant to the rules of the Nasdaq Stock Exchange.

On October 11, 2023, Akerna issued an amended and restated convertible secured promissory note ("Amended and Restated Note") to MJA which amends and restates the Secured Promissory Note dated April 28, 2023 by and between Akerna and MJA (the 'Original Note'), whereby Akerna promises to pay to the order of MJA or its registered assigns the amount of \$1,500,000. The Amended and Restated Note amended the Original Note to increase the principal amount of the Original Note from \$1,000,000 to \$1,500,000.

In connection to the MJA Note, the Security Agreement, and the Guaranty Agreement (collectively, "New Note Transaction Documents") and solely to permit Akerna to issue the MJA Note and execute and perform its obligations under the New Note Transaction Documents and a Subordination Agreement (as defined below), each of the Holders of the Senior Convertible Notes issued pursuant to the 2021 SPA agreed to waive the prohibition on issuing indebtedness other than Permitted Indebtedness (as defined in the Senior Convertible Notes) pursuant to Section 14(b) 14(b) of the Senior Convertible Notes and the prohibition permitting Liens (as defined in the Senior Convertible Notes) to exist other than Permitted Liens (as defined in the Senior Convertible Notes) pursuant to Section 14(c) 14(c) of the Senior Convertible Notes and Section 5(g) 5(g)(v) of the 2021 SPA (the "Waiver"). In connection to the New Note Transaction Documents, MJ Acquisition, Akerna, and HT Investments MA LLC (the "Senior Agent", together with the Holders, the "Senior Creditors"), as collateral agent under the 2021 SPA, each on behalf of the respective Holders, entered into a subordination and intercreditor agreement (the "Subordination Agreement"), whereby the parties agreed that the payment of any and all obligations, liabilities and indebtedness of every nature of Akerna, its applicable subsidiary and/or affiliates from time to time owed to MJ Acquisition under the Subordinated Debt Documents (as defined in the Subordination Agreement) will be subordinate and subject in right and time of payment, to the prior payment in full of all obligations under the Senior Convertible Notes.

Pursuant to the Amended and Restated Note, Akerna's obligations under the Amended and Restated Note are to be secured pursuant to an Amended and Restated Security and Pledge Agreement entered into by and among Akerna, MJA and the other parties thereto dated October 11, 2023 (the "Amended and Restated Security Agreement"). The Amended and Restated Security Agreement amends and restates the Security Agreement entered into by and among Akerna, MJA and other parties thereto dated April 28, 2023 (the "Original Security Agreement") to reflect the entry into the Amended and Restated Note and change reference therein from the Original Note to the Amended and Restated Note.

Note 6 – Income Taxes

Our effective tax rate was 0.00% 0.00% and 0.44% 0.50% for the six nine months ended June 30, 2023 September 30, 2023 and 2022, respectively. Differences between the statutory rate and our effective tax rate resulted from changes in valuation allowance and permanent differences for tax purposes in the treatment of certain nondeductible expenses. Our effective tax rate was impacted by indefinite-lived deferred tax liabilities in the 2022 period, resulting primarily from the acquisition of 365 Cannabis in 2021, which cannot be considered as a source of future taxable income available to utilize recorded deferred tax assets based on the Company's Company's scheduling and the 80% limit on the utilization of net operating loss carry forwards under current U.S. tax law. While there were none in the 2023 period, we paid nominal amounts for income taxes, net of refunds received, in certain state and national jurisdictions during the six nine months ended June 30, 2022 September 30, 2022. Uncertain tax positions of less than \$0.1 million were reversed during the six nine months ended June 30, 2022 September 30, 2022 as a result of the Internal Revenue Service's Service's dismissal of potential penalties.

Note 7 – Supplemental Balance Sheet Disclosures

Prepaid expenses and other current assets consisted of the following as of the dates presented:

	June 30,		December 31,		September 30, 2023	December 31, 2022
	2023	2022	2022	2022		
Unbilled receivables	\$ 499,330	\$ 544,212	\$ 503,029	\$ 544,212		
Software and technology	156,133	168,792	58,254	168,792		
Insurance	99,831	224,785	85,323	224,785		
Professional services, dues and subscriptions	2,986	183,614	39,069	183,614		
Deferred contract costs	1,709	36,465	–	36,465		
Other	67,315	51,755	83,874	51,755		
Total	\$ 827,304	\$ 1,209,623	\$ 769,549	\$ 1,209,623		

Accounts payable, accrued expenses, and other accrued liabilities consisted of the following as of the dates presented:

	June 30,		December 31,		September 30, 2023	December 31, 2022
	2023	2022	2022	2022		
Accounts payable	\$ 1,747,636	\$ 1,510,287	\$ 1,704,762	\$ 1,510,287		
Settlements and legal	884,428	950,213	928,715	950,213		
Contractors	411,324	562,993	434,289	562,993		
Compensation	334,865	368,440	439,617	368,440		
Sales taxes	201,610	219,285	164,473	219,285		
Professional fees	142,429	155,161	185,077	155,161		
Interest and other	273,444	660,040	469,884	660,040		
Total	\$ 3,995,736	\$ 4,426,419	\$ 4,326,727	\$ 4,426,419		

Note 8 – Commitments and Contingencies

Litigation

On May 15 and May 23, 2023, Akerna and all its directors were named in two derivative lawsuits (McCaffrey v. Akerna et al. and Caller v. Akerna et al., Nos. 1:23-cv-01213-PAB23-cv-01213-PAB and 1:23-cv-01300-KLM, 23-cv-01300-KLM, respectively) filed in the United States District Court for the District of Colorado by stockholders Albert McCaffrey and Israel Caller, respectively, alleging that the disclosures made regarding the pending transactions with Gryphon and MJ Acquisition violate Sections 14(a) and 20(a) of the Securities and Exchange Act of 1934. The lawsuits contend that the disclosures omit material information regarding the transactions and seek injunctive relief and attorneys' fees. Akerna has not yet responded to either complaint but intends to vigorously defend the lawsuits. The two actions have both been dismissed without prejudice on October 3, 2023 (Caller) and at this time, we do not believe an estimate of potential loss, if any, is appropriate. October 11, 2023 (McCaffrey).

On January 13, 2023, Courier Plus Inc. d/b/a Dutchie ("Dutchie" ("Dutchie") filed a complaint in the Court of Common Pleas, Dauphin County, Commonwealth of Pennsylvania against Akerna and MJF alleging unfair competition, tortious interference, and unjust enrichment with respect to MJF's MJF's exclusive government contract with the Commonwealth of Pennsylvania. We filed a preliminary objection alleging serious defects, such as jurisdiction. The parties attended a hearing in July 2023. In October 2023, the courts dismissed the case but left some items available in the complaint for an appeal. Dutchie has amended its complaint and are awaiting a decision from the Court. filed again. We filed another preliminary objection to their amended complaint. Before and throughout this dispute, we have worked with the Commonwealth of Pennsylvania to ensure continued compliance with our contract. We intend to continue to defend our position vigorously and, at this time, do not believe an estimate of potential loss, if any, is appropriate.

On April 2, 2021, April 2, 2021, TreCom Systems Group, Inc. ("TreCom") filed suit against Akerna and MJF in the federal District Court for the Eastern District of Pennsylvania, seeking recovery of up to approximately \$2.0 million for services allegedly provided pursuant to a Subcontractor Agreement between MJF and TreCom. MJF provided a notice of termination of the operative Subcontractor Agreement on August 4, 2020. MJF disputes the validity of TreCom's claims and the enforceability of the alleged agreement that TreCom submitted to the court. Akerna filed counterclaims against TreCom for breach of contract, a declaratory judgment, commercial disparagement, and defamation. TreCom failed to return Akerna's intellectual property and issued numerous disparaging statements to one of Akerna's clients. TreCom subsequently filed a motion to dismiss these counterclaims, which was denied by the court. court denied. Akerna intends to vigorously defend against TreCom's claims and pursue its own claims. With respect to the TreCom matter, we established a loss contingency of \$0.2 million in 2021 which remains outstanding as of June 30, 2023 September 30, 2023.

As of June 30, 2023September 30, 2023, and through the date these condensed consolidated financial statements were issued, there were no other legal proceedings requiring recognition or disclosure in the condensed consolidated financial statements.

Other
Other

In connection with the Sale Transaction and the Merger, we have a commitment to compensate our financial advisor for up to three percent of the transaction value in success fees, subject to a minimum of \$1.5 million, should the transactions be completed. In addition, we are party to arrangements with our executive officers and certain other administrative employees pursuant to their employment, retention and transaction success agreements that may result in the receipt by such executive officers and employees of cash severance payments and other transaction success bonuses and benefits with a total value of approximately **\$1.4 million** **\$1.2 million** (collectively and not individually), but not including the accelerated vesting of any equity awards held by those officers.

Operating Leases

During the first half of 2022, we began negotiations to terminate the 365 Cannabis office lease in Las Vegas, Nevada. We established an obligation of **\$0.5 million** **\$0.5 million** which is management's best estimate of the costs to exit the lease. As of **June 30, 2023** **September 30, 2023**, the lease termination matter remains unresolved.

Note 9 – Stockholders' Deficit

Common and Preferred Stock

We have one single class of Common Stock of which 150,000,000 shares are authorized with a par value of **\$0.0001** **\$0.0001** per share. The holders of Common Stock are entitled to one vote per share on all matters submitted to a vote of stockholders of the Company. Subject to the prior rights of all classes or series of stock at the time outstanding having prior rights as to dividends or other distributions, all stockholders are entitled to share equally in dividends, if any, as may be declared from time to time by the Board of Directors out of funds legally available. Subject to the prior rights of our creditors and the holders of all classes or series of stock at the time outstanding having prior rights as to distributions upon liquidation, dissolution, or winding up of the Corporation, in the event of liquidation, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of all liabilities. The stockholders do not have cumulative, preemptive rights, or subscription rights.

We also have 5,000,000 authorized shares of preferred stock, **\$0.0001** **\$0.0001** par value per share, of which one share of special voting preferred stock (the "Special Voting Preferred Stock") is issued and outstanding (see below).

On June 14, 2023, we entered into a transaction for a private investment in our public equity (the "PIPE Investment") whereby 1 million shares of Common Stock were issued to the investor at \$0.50 per share for total cash proceeds of \$0.5 million. The proceeds from the PIPE Investment were used to pay a termination fee and related expenses of \$0.2 million to POSaBIT in connection with the termination of the **MJF-Ample** **MJF-Ample** SPA and the remainder **has been allocated** **was used** for ongoing operating expenses.

Special Voting Preferred Stock and Exchangeable Shares

In connection with a prior transaction in which we acquired Ample in exchange for 3,294,574 shares of exchangeable shares (the "Exchangeable Shares"), we issued of a single share of our special voting preferred stock (the "Special Voting Preferred Stock"), for the purpose of ensuring that each Exchangeable Share is substantially the economic and voting equivalent of a share of Akerna Common Stock and that each Exchangeable Share is exchangeable on a 20-for-one basis for a share of Akerna Common Stock, subject to certain limitations and adjustments. Each holder of Exchangeable Shares effectively has the ability to cast votes along with holders of Akerna Common Stock. The Exchangeable Shares do not have a par value. The Special Voting Preferred stock has a par value of ~~\$0.0001~~ \$0.0001 per share and a preference in liquidation of ~~\$1.00~~ \$1.00. The Special Voting Preferred Stock entitles the holder to an aggregate number of votes equal to the number of the Exchangeable Shares issued and outstanding from time to time and which we do not own. The holder of the Special Voting Preferred Stock and the holders of shares of Akerna Common Stock will both vote together as a single class on all matters submitted to a vote of our shareholders. At such time as the Special Voting Preferred Stock has no votes attached to it, the share shall be automatically cancelled.

During the **six** nine months ended **June 30, 2023** **September 30, 2023**, certain Ample shareholders exchanged a total of **33,438** Exchangeable **36,168** Exchangeable Shares with a value of **\$255,877** **\$277,450** for **1,672** **1,813** shares of Akerna Common Stock. The exchanges were accounted for as equity transactions and we did not recognize a gain or loss on these transactions. As of **June 30, 2023** **September 30, 2023**, there were a total of **252,224** **249,504** exchangeable shares remaining as issued and outstanding which could be exchanged for **12,611** **12,470** shares of Akerna Common Stock.

ATM Program

In 2021, we entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc. ("Oppenheimer") and A.G.P./Alliance Global Partners ("AGP") pursuant to which we could offer and sell from time to time, up to **\$25 million** **\$25 million** of shares of our Common Stock through an "at the market" equity offering program (the "2021 ATM Program"). From its inception through September 23, 2022, a total of 118,629 shares of Common Stock with an aggregate gross purchase price of \$2.7 million, including 90,809 shares with an aggregate gross purchase price of \$0.8 million sold during 2022, were sold under the 2021 ATM Program. On September 23, 2022, we, Oppenheimer and AGP mutually agreed to terminate the 2021 ATM Program.

On September 28, 2022, we entered into a new agreement with AGP pursuant to which we may offer and sell up to **\$20.0 million** **\$20.0 million** of shares of our Common Stock (the **the** "2022 ATM Program") from time to time through AGP as the sales agent for which they will receive a commission of 3.0% of the gross proceeds. The 2022 ATM Program is currently limited to less than \$0.4 million due to certain restrictions imposed by the registration statement underlying the offering (the "Baby Shelf Limitation"). Under the Baby Shelf Limitation, we may not offer Common Stock under the registration statement with a value of more than one-third of the aggregate market value of our Common Stock held by non-affiliates in any twelve-month period, so long as the aggregate market value of our Common Stock held by non-affiliates is less than \$75.0 million. Net proceeds from the sale of Common Stock under the 2022 ATM Program have been and may continue to be used for general corporate purposes including working capital, marketing, product development and capital expenditures. Through December 31, 2022, we sold a total of 552,148 shares of Common Stock with an aggregate gross purchase price of \$1.1 million under the 2022 ATM Program. There were no offerings of Common Stock under the 2022 ATM program during the **six** **nine** months ended **June 30, 2023** **September 30, 2023**.

2022 Unit Offering

On July 5, 2022, we completed the 2022 Unit Offering which was comprised of an aggregate of (i) 29,382,861 units consisting of 1,469,143 shares of Common Stock together with Common Stock warrants (the "Common Warrants") to purchase up to 1,469,143 shares of Common Stock (together, the "Units") and (ii) 14,095,400 pre-funded units, consisting of 14,095,400 pre-funded warrants ("Pre-funded Warrants") to purchase 704,770 shares of Common Stock, together with Common Warrants to purchase up to 704,770 shares of Common Stock (together, the "Pre-funded Pre-funded Units"). The Units were sold at a public offering price of \$0.23 per unit and the Pre-funded Units were sold at a public offering price of \$0.2299 per pre-funded unit. The Pre-Funded Warrants were exercised immediately thereafter at their nominal exercise price of ~~\$0.002~~ \$0.002 per share. The Common Warrants accompanying each of the Units and Pre-funded Units were issued separately and are immediately tradeable separately upon issuance. The Common Warrants had an original exercise price of ~~\$4.60~~ \$4.60 per share subject to certain adjustments, are immediately exercisable and will expire five years from the date of issuance. In connection with a convertible redeemable preferred stock offering in October 2022, the exercise price of the Common Warrants was reduced to \$3.518 per share effective October 5, 2022 and reduced to \$0.88 per share effective January 27, 2023 as a result of the lowering of the conversion price for the Convertible Notes in connection with the Exchange Agreements. In connection with the PIPE Investment, the **the** exercise price of the Common Warrants was further reduced from \$0.88 per share to \$0.37 per share.

In addition, we issued to the Underwriter warrants to purchase additional shares of Common Stock (the "Underwriter Warrants"). The Underwriter Warrants provided for the purchase of up to 108,696 shares of Common Stock. The Underwriter Warrants are exercisable at any time and from time to time, in whole or in part, commencing from six months after June 29, 2022 (the "Effective Date") and ending five years from the Effective Date, at a price per share equal to \$4.60, subject to certain **adjustments**. In connection with a convertible redeemable preferred stock offering in October 2022, the exercise price of the Underwriter Warrants was reduced to \$3.518 per share effective October 5, 2022 and reduced to \$0.88 per share effective January 27, 2023 as a result of the lowering of the conversion price for the Convertible Notes in connection with the Exchange **Agreements**. In connection with the PIPE Investment, the exercise price of the Underwriter Warrants was further reduced from \$0.88 per share to \$0.37 per share. The Underwriter Warrants may be transferred by the Underwriter without restriction during the same period.

As of **June 30, 2023** **September 30, 2023**, a total of 45,652,174 warrants exercisable for 2,282,609 shares of Common Stock remain outstanding from the 2022 Unit Offering including 43,478,261 Common Warrants exercisable for 2,173,913 shares of Common Stock and 2,173,913 Underwriter Warrants exercisable for 108,696 shares of Common Stock. In accordance with our policy, we assessed the warrants issued in connection with the 2022 Unit Offering and determined that there are no instances outside of the Company's control that could require cash settlement. In addition, we determined that the warrants issued in connection with the 2022 Unit Offering do not meet the definition of a derivative as they are indexed to the Company's Common Stock and they satisfy all of the additional qualifications to be classified within equity. Through **June 30, 2023** **September 30, 2023**, the Common Warrants and Underwriter Warrants remain classified within equity.

2019 Warrants

In connection with MTech's initial public offering, MTech sold units consisting of one share of MTech's common stock and one warrant of MTech ("MTech Public Warrant"). Each MTech Public Warrant entitled the holder to purchase one share of MTech's common stock. Concurrently with MTech's initial public offering, MTech sold additional units on a private offering basis. Each of these units consisted of one share of MTech's common stock and one warrant of MTech ("MTech Private Warrant"). Each MTech Private Warrant entitled the holder to purchase one share of MTech's common stock.

Upon completion of the Mergers between MTech and MJF on June 17, 2019, the MTech Public Warrants and the MTech Private Warrants were converted to the 2019 Public Warrants and Private Warrants, respectively, at an exchange ratio of one-for-one to a warrant to purchase one share of Akerna's Common Stock with identical terms and conditions. Concurrent with our 20-for-1 reverse stock split during the fourth quarter of 2022, the exchange ratio of the 2019 Public Warrants and the Private Warrants was changed to 20 warrants for one share of Common Stock. The Private Warrants have contingent exercise provisions such that when the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company. Accordingly, the requirements for accounting for the Private Warrants as equity are not satisfied and the Private Warrants have been reflected on our consolidated balance sheets as a derivative liability and are not included in the summary of outstanding warrants presented below.

Outstanding Warrants

The following table summarizes our warrants outstanding as of the dates presented:

	Exercise Price	Expiration Date	Balance as of December 31, 2022	Issued	Exercised	Expired	Balance as of September 30, 2023
2019 Public Warrants (1)	\$ 230.00	6/19/2024	5,813,804	—	—	—	5,813,804
2022 Unit Offering							
Common Warrants (2)	\$ 0.37	6/29/2027	43,478,261	—	—	—	43,478,261
Underwriter Warrants (2)	\$ 0.37	6/29/2027	2,173,913	—	—	—	2,173,913
			51,465,978	—	—	—	51,465,978

(1) The 2019 Public Warrants are exercisable for 290,690 shares of Common Stock at \$230.00 per share or a ratio of 20 warrants for one share of Common Stock.

(2) In connection with the PIPE Investment, the exercise price of the Common Warrants and Underwriter Warrants was reduced from \$0.88 per share to \$0.37 per share and are exercisable for a combined amount of 2,282,609 shares of Common Stock at \$0.37 per share or a ratio of 20 warrants for one share of Common Stock.

	Exercise Price	Expiration Date	Balance as of December 31, 2022	Balance as of June 30, 2023
(1) The 2019 Public Warrants are exercisable for 290,690 shares of Common Stock at \$230.00 per share or a ratio of 20 warrants for one share of Common Stock.				June 30, 2023
(2) In connection with the PIPE Investment, the exercise price of the Common Warrants and Underwriter Warrants was reduced from \$0.88 per shares to \$0.37 per share and are exercisable for a combined amount of 2,282,609 shares of Common Stock at \$0.37 per share or a ratio of 20 warrants for one share of Common Stock.				
Common Warrants (2)	\$ 0.37	6/29/2027	43,478,261	—
Underwriter Warrants (2)	\$ 0.37	6/29/2027	2,173,913	—
			51,465,978	—

Note 10- Fair Value

Fair Value Option Election - Convertible Notes

We elected to account for the Senior Convertible Notes by applying the fair value option. Under the fair value option, the financial liability is initially measured at its issue-date estimated fair value and subsequently remeasured at its estimated fair value on a recurring basis at each reporting period date. The change in estimated fair value resulting from changes in instrument-specific credit risk is recorded in other comprehensive loss as a component of equity. The remaining estimated fair value adjustment is presented as a single line item within Other (expense) income in our condensed consolidated statements of operations under the caption, Change in fair value of convertible notes.^{notes}.

For the Senior Convertible Notes, which are measured at fair value categorized within Level 3 of the fair value hierarchy, the following represents a reconciliation of the fair values for the three and six^{nine} months ended June 30, 2023 September 30, 2023 and June 30, 2022 September 30, 2022:

	Three Months Ended				Three Months	
	June 30,		June 30,		Ended September 30,	
	2023	2022	2023	2022	2023	2022
Fair value balance at beginning of period	\$8,462,000	\$15,337,000	\$14,607,000	\$17,305,000	\$ 9,265,000	\$
Principal payments in cash and Common Stock	(115,000)	(2,080,000)	(6,429,457)	(5,380,000)	(1,500,000))
Change in fair value reported in the statements of operations	893,000	294,000	1,048,457	1,727,000	(185,000))
Change in fair value reported in other comprehensive loss	25,000	(163,000)	39,000	(264,000)	3,000	
Fair value balance at end of period	\$9,265,000	\$13,388,000	\$ 9,265,000	\$13,388,000	\$ 7,583,000	\$

The estimated fair value of the Senior Convertible Notes was computed using Monte Carlo simulations, which incorporates significant inputs that are not observable in the market, and thus represents a Level 3 measurement as defined by GAAP. The unobservable inputs utilized for measuring the fair value of the Senior Convertible Notes reflect our assumptions about the assumptions that market participants would use in valuing the Senior Convertible Notes as of its issuance date and subsequent reporting periods.

We estimated the fair value by using the following key inputs to the Monte Carlo Simulation Models:^{Models}:

Fair Value Assumptions			September 30, 2023		December 31, 2002	
			June 30, 2023	December 31, 2022	2023	2002
	Convertible Notes					
Face value principal payable	8,233,271	14,662,727	\$	6,733,271	\$	14,662,727
Original conversion price	4.75	4.75	\$	4.75	\$	4.75
Value of Common Stock	0.605	0.69	\$	0.22	\$	0.69
Expected term (years)	1.3	1.8		1.0		1.8
Volatility	111 %	77 %		102 %		77 %
Market yield	41.7 %	44.3 %		41.2 %		44.3 to 43.9 %

Risk free rate	4.9	%	4.4	%	4.7	%	4.4	
Issue date	October 5, 2021		October 5, 2021		October 5, 2021		October 5, 2021	
Maturity date	October 5, 2024		October 5, 2024		October 5, 2024		October 5, 2024	

20

Fair Value Measurement - Private Warrants

For the Private Warrants, which are classified as derivative liabilities on our condensed consolidated balance sheets and are measured at fair value categorized within Level 3 of the fair value hierarchy, the following represents a reconciliation of the fair values for the three and six months ended June 30, 2023 September 30, 2023 and June 30, 2022 September 30, 2022:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
Fair value balance at beginning of period	\$ —	\$ 45,127	\$ —	\$ 63,178
Change in fair value reported in the statements of operations		(\$33,845)		(51,896)
Fair value balance at end of period	\$ 2023	\$ 11,282	\$ 2023	\$ 11,282
Fair value balance at beginning of period	\$ —	\$ 45,127	\$ —	\$ 63,178
Change in fair value reported in the statements of operations		(33,845)		(51,896)
Fair value balance at end of period	\$ —	\$ 11,282	\$ —	\$ 11,282

We utilized a binomial lattice model, which incorporates significant inputs, specifically the expected volatility, that are not observable in the market, and thus represents a Level 3 measurement as defined in GAAP. The unobservable inputs utilized for measuring the fair value of the Private Warrants reflect our estimates regarding the assumptions that market participants would use in valuing the Warrants as of the end of the reporting periods.

We recognize changes to the derivative liability against earnings or loss each reporting period. Upon exercise of the Private Warrants, holders will receive a delivery of Akerna shares on a net or gross share basis per the terms of the Private Warrants and any exercise will reclassify the Private Warrants, at the time of exercise, to shareholder's equity to reflect the equity transaction. There are no periodic settlements prior to the holder exercising the Private Warrants. There were no transfers in or out of Level 3 from other levels for the fair value hierarchy. The value of the private warrants was assessed to be zero as of September 30, 2023.

We estimated the fair value by using the following key inputs:

	September 30,		December 30,	
	2023	2022	2023	2022
Fair Value Assumptions - Private Warrants				
Number of Private Warrants		225,635		225,635
Original conversion price	\$ 230	\$ 230.00		
Value of Common Stock	\$ 0.605	\$ 0.69		
Expected term (years)	0.96	1.46		
Volatility	NM	NM		
Risk free rate	NM	NM		

NM - Not meaningful.

	December 31,	
	June 30, 2023	2022
Fair Value Assumptions - Private Warrants		
Number of Private Warrants	225,635	225,635
Original conversion price - 2022 Unit Offering Common and Underwriter Warrants	\$ 230	\$ 230.00
Value of Common Stock	\$ 0.605	\$ 0.69
Expect The fair value of the Common Warrants and Underwriter Warrants issued in connection with our 2022 Unit Offering represent a measurement within Level 3 of the fair value hierarchy and were estimated based on the following key inputs as of the date of the 2022 Unit Offering: Volatility	NM	NM
Risk free rate - 2022 Common and Underwriter Warrants	NM	July 5, 2022
NM - Not meaningful.		
Fair Value Assumptions - 2022 Common and Underwriter Warrants		
Exercise price	\$ 4.60	\$ 4.60
Expected term (years)	5.0	5.0
Volatility	136.9%	136.9%

We utilized a Black-Scholes-Merton option pricing model, which incorporates significant inputs, specifically the expected volatility, that are not observable in the market, and thus represents a Level 3 measurement as defined in GAAP. The unobservable inputs utilized for measuring the fair value of the Common and Underwriter Warrants reflect our estimates regarding the assumptions that market participants would have used in valuing the Warrants as of the date of the 2022 Unit Offering or July 5, 2022. The fair value of the Common Warrants and Underwriter Warrants was recorded in equity as a component of the net proceeds received from the 2022 Unit Offering (see Note 9).

Note 11 – Earning per Share

During the three and nine months ended **June 30, 2023****September 30, 2023** and 2022, we used the two-class method to compute net loss per share because we issued securities other than common stock that are economically equivalent to a common share in that the class of stock has the right to participate in dividends should a dividend be declared payable to holders of Akerna Common Stock. These participating securities were the Exchangeable Shares issued by our wholly owned subsidiary in exchange for our acquired ownership interest in Ample. The two-class method requires earnings for the period to be allocated between the Common Stock and participating securities based on their respective rights to receive distributed and undistributed earnings. Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of Common Stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the **period's** earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the Exchangeable Shares have no obligation to fund losses.

Diluted net loss per common share is calculated under the **two-class****two-class** method by giving effect to all potentially dilutive common stock equivalents, including warrants, restricted stock, restricted stock units, and shares of common stock issuable upon conversion of our Senior Convertible Notes. We analyzed the potential dilutive effect of any outstanding convertible securities under the **"if-converted"****"if-converted"** method, in which it is assumed that the outstanding Exchangeable Shares and the Senior Convertible Notes, are converted to shares of Common Stock at the beginning of the period or date of issuance, if later. We report the more dilutive of the approaches **(two-class (two-class or if-converted)if-converted)** as the diluted net loss per share during the period. The dilutive effect of unvested restricted stock and restricted stock units is reflected in diluted loss per share by application of the treasury stock method and is excluded when the effect would be anti-dilutive.

The weighted-average number of shares outstanding used in the computation of diluted earnings per share does not include the effect of potential outstanding common shares that would have been anti-dilutive for the period. The table below details potentially outstanding shares on a fully diluted basis that were not included in the calculation of diluted earnings per share for the periods presented:

	Nine Months Ended September 30,	
	2023	2022
	12,476	14,284
Shares issuable upon exchange of Exchangeable Shares	12,476	14,284
Shares of common stock issuable upon conversion of convertible notes	13,466,543	2,354,268
Warrants		
2019 Public Warrants	290,690	290,690
2022 Unit Offering - Common Warrants	2,173,913	2,173,913
2022 Unit Offering - Underwriter Warrants	108,696	108,696
Unvested restricted stock units	6,498	730
Unvested restricted stock awards	—	334
Total	16,058,816	4,942,916
Six Months Ended June 30,		
	2023	2022
	12,611	14,560
	1,733,321	2,354,268
Warrants		
2019 Public Warrants	290,690	290,690
2022 Unit Offering - Common Warrants	2,173,913	—
2022 Unit Offering - Underwriter Warrants	108,696	—
Unvested restricted stock units	9,347	22,283
Unvested restricted stock awards	—	334
Total	4,328,578	2,682,135

Note 12 – Discontinued Operations

During the quarter ended December 31, 2022, we committed to a strategic shift in our business strategy for 2023 and beyond including the sale of 365 Cannabis and LCA, or the Discontinued Group. Subsequent to the sales of 365 Cannabis and LCA that were completed in January 2023, we have no future involvement or relationships with these businesses. As a result of these actions, the assets and liabilities and results of operations of the Discontinued Group have been classified as held for sale and discontinued operations, respectively, for all periods presented.

The following table presents the major classes of assets and liabilities of the Discontinued Group:

	As of December		As of	As of
	As of June 30, 2023	31, 2022	September 30, 2023	December 30, 2022
Cash and restricted cash	\$ —	305,500	\$ —	\$ 305,500
Accounts receivable, net	—	112,444	—	112,444
Prepaid expenses & other current assets	—	578,393	—	578,393
Fixed assets	—	63,764	—	63,764
Capitalized software, net	—	828,555	—	828,555
Intangible assets, net	—	3,241,372	—	3,241,372
Total assets held for sale	\$ —	5,130,028	\$ —	\$ 5,130,028
Accounts payable, accrued expenses and other current liabilities	\$ —	1,034,426	\$ —	\$ 1,034,426
Deferred revenue	—	994,713	—	994,713
Deferred revenue, noncurrent	—	217,083	—	217,083
Total liabilities held for sale	\$ —	2,246,222	\$ —	\$ 2,246,222

The following table summarizes the results of operations of the Discontinued Group:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
Revenue	\$ —	\$ 2,596,205	\$ 214,346	\$ 5,301,966
Cost of revenue	—	660,717	10,119	1,341,379
Gross profit	—	1,935,488	204,227	3,960,587
Product development	—	486,056	117,500	875,670
Sales and marketing	—	1,206,228	171,753	2,391,207
General and administrative	—	65,019	4,032	713,120
Depreciation and amortization	—	540,272	24,507	1,052,219
Impairment of long-lived assets	—	9,006,222	—	9,037,642
Other expense (income), net	—	(303,930)	1,833	(303,930)
Loss from discontinued operations before income taxes	—	—	—	—
Income tax benefit	\$ —	\$ 2,348,423	\$ 214,346	\$ (9,805,341)
Cost of revenue	—	575,076	10,119	—
Loss from discontinued operations, net of tax	—	(9,064,379)	(115,398)	(9,805,341)
Gross profit	—	1,773,347	204,227	5,733,935
Gain on sale of discontinued operations, net of tax	—	—	—	—
Product development	—	414,948	117,500	1,290,618
Gain (loss) from discontinued operations, net of tax	\$ —	\$ 928,221	\$ 171,753	\$ 3,19428
General and administrative	—	(3,006,140)	4,032	(2,596,946)
Depreciation and amortization	—	567,259	24,507	1,619,478
Impairment of long-lived assets	—	—	—	9,037,642
Other expense (income), net	—	849	1,833	(304,526)
Gain (loss) from discontinued operations before income taxes	—	2,869,908	(115,398)	(7,240,811)
Income tax benefit	—	—	—	—
Gain (loss) from discontinued operations, net of tax	—	2,869,908	(115,398)	(7,240,811)
Gain on sale of discontinued operations, net of tax	—	—	212,601	—
Net gain (loss) from discontinued operations, net of tax	\$ —	\$ 2,869,908	\$ 97,203	\$ (7,720,811)

The impairment of long-lived assets for the **six** **nine** months ended **June 30, 2023** **September 30, 2023** is attributable to goodwill associated with 365 Cannabis (\$9.0 million) and LCA (less than \$0.1 million). Other expense (income), net includes a reversal of bad debt expense of \$0.3 million during the 2022 periods. We recognized a gain on the disposition of the Discontinued Group as the sum of the cash proceeds received, or \$0.6 million, and the termination and release of the Earn-out Obligation, or \$2.3 million, exceeded the carrying values of \$2.7 million attributable to the net assets of the Discontinued Group upon their dispositions in January 2023. While there were none during the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, the Discontinued Group incurred capital expenditures for capitalized software assets of **\$0.6 million** **\$0.9 million** for the **six** **nine** months ended **June 30, 2023** **September 30, 2022**. There were no material non-cash investing and financing activities attributable to the Discontinued Group for the **six** **nine** months ended **June 30, 2023** **September 30, 2023** and 2022, respectively.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements for the three and **six** nine months ended **June 30, 2023** **September 30, 2023**, and the related notes thereto, which have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP").

Akerna Corp., herein referred to as "we", "us", "our," the "Company" "Company" or "Akerna", through our wholly-owned subsidiaries MJ Freeway, LLC ("MJF"), Ample Organics, Inc. Inc. ("Ample"), Trellis Solutions, Inc. ("Trellis"), solo sciences, inc. ("Solo") and Viridian Sciences Inc. ("Viridian") provides software as a service ("SaaS") solutions within the cannabis industry that enable regulatory compliance and inventory management management.

Forward-Looking Statements

This Quarterly Report on Form 10-Q including all exhibits hereto contain contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future events or our future results of operations, financial condition, business, strategies, financial needs, and the plans and objectives of management. In some cases, forward-looking statements can be identified because they contain words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "likely," "plan," "potential," "predict," "project," "seek," "should," "target," "will," "would" or similar expressions and the negatives of those terms. Forward-looking statements are based on information available to our management as of the date of this Quarterly Report and our management's management's good faith belief as of such date with respect to future events and are subject to a number of risks, uncertainties, and assumptions that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

- Our merger transaction (the "Merger") with Gryphon Digital Mining Inc. ("Gryphon") is subject to a number of risks, including risks regarding whether the Merger will be completed, the timing for completion and the market price of the common stock following completion of the Merger; Merger;
- our sale transaction (the "Sale Transaction") with MJ Freeway Acquisition Co ("MJ Acquisition"), an affiliate of Alleva, Inc., ("Alleva") is subject to a number of risks, including risks regarding whether the Sale Transaction will be completed and the timing for completion; completion;
- our Merger and Sale Transaction are subject two lawsuits filed on behalf of stockholders of the Company which could affect our ability to close either transaction; transaction;
- our ability to continue as a going concern and manage our cash flow; flow;
- our ability to sustain revenues, to achieve or maintain profitability, and to effectively manage our growth; growth;
- our short operating history makes it difficult to evaluate our business and future prospects; prospects;
- our dependence on the commercial success of our clients, the continued growth of the cannabis industry and the regulatory environment in which the cannabis industry operates
- our ability to attract new clients on a cost-effective basis and the extent to which existing clients renew and upgrade their subscriptions; subscriptions;
- the timing of our introduction of new solutions or updates to existing solutions; solutions;
- our ability to successfully diversify our solutions by developing or introducing new solutions; solutions;
- our ability to respond to changes within the cannabis industry, including legal and regulatory changes; changes;
- the effects of adverse changes in, or the enforcement of, federal laws regarding our clients' cannabis operations or our receipt of proceeds from such operations; operations;
- our ability to manage unique risks and uncertainties related to government contracts; contracts;
- our ability to manage and protect our information technology systems; systems;
- our ability to maintain and expand our strategic relationships with third parties; parties;
- our ability to deliver our solutions to clients without disruption or delay; delay;
- our exposure to liability from errors, delays, fraud, or system failures, which may not be covered by insurance; insurance;
- our ability to expand our international reach; reach;
- our ability to retain or recruit officers, key employees, and directors; directors;
- our ability to raise additional capital or obtain financing in the future; future;
- our response to adverse developments in the general market, business, economic, labor, regulatory, and political conditions, including worldwide demand for cannabis and the spot price and long-term contract price of cannabis; cannabis;

- our response to competitive risks; risks;
- our ability to protect our intellectual property; property;
- the market reaction to negative publicity regarding cannabis; cannabis;
- our ability to manage the requirements of being a public company; company;
- our ability to service our convertible debt and meet ongoing covenants; covenants;
- risks related to our shares of common stock remaining listed on the Nasdaq Capital Market; Market;
- other factors discussed in other sections of this Quarterly Report on Form 10-Q, including the sections of this report titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and under Part II, Item 1A. "Risk Factors" and in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission, or the SEC, on March 20, 2023March 20, 2023 under Part I, Item 1A, "Risk Factors."

24

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated, or expected. We caution readers not to place undue reliance on any such forward-looking forward-looking statements, which speak only as of the date made. We disclaim any obligation to revise subsequently any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. We qualify all the forward-looking statements contained in this Quarterly Report by the foregoing cautionary statements.

Business Overview

Akerna is a leading provider of software solutions within the cannabis industry that enable regulatory compliance and inventory management through our wholly-owned subsidiaries MJF, Ample, Trellis, Solo and Viridian. Our proprietary suite of solutions are adaptable for industries in which interfacing with government regulatory agencies for compliance purposes is required, or where the tracking of organic materials from seed or plant to end products is desired. We also develop products intended to assist states in monitoring licensed businesses' compliance with state regulations and to help state-licensed businesses operate in compliance with such law. We provide our commercial software platform, MJ Platform®, Trellis®, Ample and Viridian to state-licensed businesses, and our regulatory software platform, Leaf Data Systems®, to state government regulatory agencies. Our MJF, Ample, Solo and Trellis solutions are considered non-enterprise offerings ("Non-Enterprise" Non- Enterprise") that meet the needs of our small and medium business ("SMB") and government regulatory agency customers while our Viridian solutions are considered enterprise offerings ("Enterprise"). We offer our software solutions to our customers as a subscription-based service. Subscription fees are based upon the chosen package which includes differentiated platform capabilities, support and user accounts. As customers recognize the value of our platform, we increasingly engage with them to facilitate broad adoption across other parts of their business.

As discussed in further detail below, we committed to a strategic shift in business strategy that resulted in the disposition and sale of two of our business units, The NAV People, Inc. d.b.a. 365 Cannabis ("365 Cannabis") and Last Call Analytics ("LCA"), in January of 2023. The sale of 365 Cannabis in addition to the planned discontinuation of Viridian represents our exit from the Enterprise software business. The sale of LCA, also in January 2023, represents a sale of certain non-core assets in advance of the Sale Transaction (as defined below) for our remaining SMB and government regulatory software service business conducted through MJF and Ample. Absent any offers for the acquisition of our Solo and Trellis platforms prior to the end of the second quarter of 2023, we plan to discontinue these business units as most of their contracts with existing clients expired in the second quarter of 2023. We have committed to winding down and terminating terminated these businesses prior to during the third quarter of 2023 in advance of the Merger (as defined below) and Sale Transaction.

Key Developments

The following general business developments had or may have a significant impact on our results of operations, financial position and cash flows.

Strategic Shift in Business Strategy

During the fourth quarter of 2022, we committed to a number of significant actions described below that collectively represent a strategic shift in our business strategy for 2023 and beyond.

Exiting the Enterprise Software Business

The development of our Enterprise software business unit, which began with the acquisitions of Viridian and 365 Cannabis in 2021, did not achieve a sustainable scale in a timely manner consistent with our original plans. Accordingly, we committed to an effort to market this business unit during the fourth quarter and on January 11, 2023, we completed the sale of 365 Cannabis to 365 Holdco (the "Buyers" "Buyers") pursuant to a stock purchase agreement (the "365 SPA") for (i) cash in the amount of \$0.5 million and the (ii) the termination and release of our obligation to the Buyers for contingent consideration in connection with our original acquisition of 365 Cannabis from the Buyers in 2021(the "Earn-out Obligation"). In accordance with the 365 SPA, we and the Buyers agreed that the value of the Earn-out Obligation was \$2.3 million for purposes of the sale of 365 Cannabis and was reflected on our condensed consolidated balance sheets as Contingent consideration payable on December 31, 2022. In connection with the sale of 365 Cannabis, we terminated certain employees that were not requested to transfer with the business by the Buyers or whose positions were no longer necessary to support our reduced level of operations. We incurred and paid restructuring charges associated with this action for less than \$0.1 million, primarily in the form of severance and related employee benefits, during the first quarter of 2023. The charges were included as a component of Cost of revenues in our condensed consolidated statements of operations.

While we explored similar sale options for Viridian, we were unable to commit to any definitive transaction. Accordingly, we informed Viridian's customers that we do not plan to continue software and support services beyond the date of existing contracts, most of which expired during the first half of 2023. With the sale of 365 Cannabis and our commitment to wind down the operations of Viridian, we have effectively exited the Enterprise software business. Accordingly, we have suspended efforts to seek any new revenue generating opportunities and will only service the existing customers of Viridian in connection with our contractual commitments. We have committed to winding down and terminating this business during the third quarter of 2023 in advance of the Merger and Sale Transaction.

25

Disposal of Non-Core SMB Software Products and Brands

In addition to the our exit from the Enterprise software business, we initiated efforts to explore a sales process for the non-core components and brands of our SMB/Non-Enterprise business unit, including Trellis, a cultivation and compliance software platform, Solo, a seed-to-sale tagging and tracking software platform and LCA, a retail analytics platform and wholly-owned subsidiary of Ample. On January 31, 2023, we completed the sale of LCA for cash in the amount of \$0.1 million. While we pursued sale opportunities for Trellis and Solo, we were ultimately unable to commit to any definitive transactions. Accordingly, we have communicated with the remaining customers of those businesses that we will discontinue software service and support upon the expiration of existing contracts, most of which occurred during the first half of 2023. Similar to Viridian, as discussed above, we have suspended efforts to seek any new revenue generating opportunities and will only service the existing customers of Solo and Trellis in connection with our contractual commitments. We have committed to winding down and terminating these businesses during the third quarter of 2023 in advance of the Merger and Sale Transaction.

Exit Strategy

With the completion of the sales of 365 Cannabis and LCA and the commitment to effectively discontinue and wind down the termination of operations and service associated with Viridian, Solo and Trellis, our remaining core SMB and governmental business unit is comprised of MJF and Ample. Concurrent with the actions described above, we entered into letters of intent with two unrelated parties in the fourth quarter of 2022 to (i) explore the sale of our remaining core SMB and governmental business unit and (ii) realize the potential value of our publicly-held holding company through a merger or similar transaction. Collectively, pursuit of these transactions reflects our intention to fully exit the SaaS industry.

On January 27, 2023, we entered into a securities purchase agreement ("MJF-Ample SPA") with POSaBIT Systems Corp ("POSaBIT") to sell MJF and Ample for \$4.0 million \$4.0 million in cash. Subsequently, we received a superior offer from Alleaves, as described below, which was presented to POSaBIT for an opportunity to match or exceed Alleave's Alleave's offer in accordance with the MJF-Ample SPA. POSaBIT ultimately declined to present a counter-offer and on April 5, 2023, we terminated the MJF-Ample SPA. As a result of the termination, Akerna paid POSaBIT a termination fee and reimbursement for expenses of \$0.2 million in June 2023. These costs were included as Other expense, net in our condensed consolidated statements of operations.

On January 27, 2023, January 27, 2023, we entered into an agreement and plan of merger (the "Merger Agreement") with Gryphon and Akerna Merger Co. ("Akerna Merger") (the "Merger"). Upon the terms and subject to the satisfaction of the conditions provided in the Merger Agreement, including the approval of the transaction by Akerna's and Gryphon's stockholders, the Merger will be effectuated with Akerna Merger merging with and into Gryphon, with Gryphon surviving the Merger as a wholly-owned subsidiary of Akerna. Following the closing of the Merger, the former Gryphon and Akerna stockholders immediately before the Merger are expected to own approximately 92.5 percent and 7.5 percent, respectively, of the outstanding capital stock on a fully diluted basis. Upon completion of the Merger, Akerna will change its name to Gryphon Digital Mining, Inc. The closing of the Merger is subject to customary closing conditions including the required approval of the stockholders of Akerna and Gryphon, the approval of the Nasdaq Capital Market (the "Nasdaq Market") of the continued listing of Gryphon after the closing of the Merger and the simultaneous closing of the Sale Transaction, among others. We and Gryphon may terminate the Merger upon mutual consent and either party may terminate the Merger unilaterally under certain conditions. In the event either party terminates the Merger pursuant to certain conditions, we will be required to pay Gryphon a termination fee of \$275,000 less any reimbursed expenses. The Merger is expected to be treated by Akerna as a reverse merger, or a change of control, whereby the stockholders of Gryphon will have majority ownership and control of Akerna after the transaction is complete.

On April 28, 2023, we entered into a securities purchase agreement (the "SPA") with MJ Freeway Acquisition Co. ("MJ Acquisition"), an affiliate of Alleaves. Upon the terms and subject to the satisfaction of the conditions described in the SPA, including approval of the transaction by Akerna's stockholders, Akerna will sell MJF and Ample to MJ Acquisition for a purchase price of \$5.0 million, \$5.0 million, consisting of \$4.0 million \$4.0 million in cash at closing and a loan by MJ Acquisition to Akerna in the principal amount of \$1.0 million \$1.0 million evidenced by a note and security documents (as described in detail below) with such note to be deemed paid in full upon closing (the "Sale Transaction"). The purchase price is subject to adjustment at closing of the Sale Transaction attributable to variances from target working capital (as set forth in the SPA) and further adjustment post-closing upon delivery of a post-closing statement by MJ Acquisition within 75 days after the closing subject to a \$0.5 million \$0.5 million cap on any post-closing working capital adjustments. The closing of the Sale Transaction is subject to customary closing conditions as well as the required approval of the stockholders of Akerna and the simultaneous closing of the merger transaction, as described below. The obligation of MJ Acquisition to close on the Sale Transaction is also subject to satisfaction of certain additional conditions regarding employee retention and contractual matters associated with MJF's MJF's and Ample's Ample's customers, among others, others. Under the SPA, Akerna and MJ Acquisition have agreed to provide limited indemnification to each other with respect to certain tax matters, in each case capped at a maximum amount of \$0.5 million. \$0.5 million. We or MJ Acquisition may terminate the SPA upon mutual consent and either party may terminate the SPA unilaterally under certain conditions as described in the SPA. In the event that MJ Acquisition or Akerna terminates the SPA pursuant to certain of the sections set forth above, Akerna will be required to pay MJ Acquisition a termination fee of \$290,000 \$290,000 and reimburse MJ Acquisition for its reasonable fees and expenses up to \$60,000. \$60,000.

26

On June 14, 2023, the Merger Agreement was amended to add the defined term "Closing Acquiror Share Price" and amend and restate the definition of "Merger Consideration." The term "Closing Acquiror Share Price" means the last reported sale price per share of Akerna Common Stock on Nasdaq on the second business day prior to the closing date of the Merger and the term "Merger Consideration" means the greater of (a) a number of shares of Akerna Common Stock equal to (i) the quotient obtained by dividing (A) Akerna's fully diluted share number, as defined in the Merger Agreement, by (B) 0.075, minus (ii) the Akerna's fully diluted share number minus (iii) the adjusted warrant share reserve number, as defined in the Merger Agreement, and (b) a number of shares of Akerna's Common Stock equal to the quotient obtained by dividing (i) \$115,625,000 by (ii) the Closing Acquiror Share Price. The amendment effectively sets a floor of \$115.6 million for the value attributable to Gryphon in the determination of post-Merger ownership.

Exchange Agreements

In connection with and in support of the Sale Transaction and the Merger, we and each of the holders of the 2021 Senior Secured Convertible Notes (the "Senior Convertible Notes") entered into exchange agreements (the "Exchange Agreements") whereby the holders would ultimately convert the principal amounts of each of their note holdings to a level that would represent 19.9 percent of the outstanding shares of our common stock, \$0.0001 par value ("Common Stock") prior to the closing of the Sale Transaction and the Merger. Immediately prior to the stockholder vote required for the closing of those transaction, the remaining Senior Convertible Notes outstanding would be converted into a special class of exchangeable preferred stock to facilitate the required stockholder vote and then be converted into shares of our Common Stock subject to the Merger. For a limited period, the conversion price of the Senior Convertible Notes was lowered to \$1.20 per share from \$4.75 per share. During the three months ended March 31, 2023, the holders of the Senior Convertible Notes converted a total of \$1.4 million of principal for 1,164,251 shares of Common Stock at the lowered price of \$1.20 per share. In connection with an equity offering in June 2023 (see below), the conversion price was further reduced to \$0.50 per share. We anticipate scheduling a meeting of stockholders during the third quarter of 2023 to approve the Sale Transaction and the Merger and we expect these transactions to close shortly thereafter.

Secured Note and Ancillary Agreements

On May 3, 2023, we received a loan in the amount of \$1.0 million from MJ Acquisition in connection with the Sale Transaction. Accordingly, we and MJ Acquisition entered into a \$1.0 million secured promissory note (the "MJA Note"). The MJA Note bears simple interest at the rate of ten percent (10%) per annum from the date of issuance until repayment of the MJA Note which will be due and payable on April 28, 2024, or, upon completion Sale Transaction, in which case the MJA Note shall be deemed paid in full. Akerna's obligations under the MJA Note have been secured pursuant to a Security and Pledge Agreement (the "Security Agreement"). The Security Agreement creates a security interest in all of the personal property of Akerna and certain of its subsidiaries. In addition, certain subsidiaries of Akerna entered into a guaranty agreement with MJ Acquisition (the "Guaranty Agreement") under which they will guarantee the obligations of the Company under the Security Agreement and the MJA Note.

On September 28, 2023 Akerna, Akerna Exchange and MJA entered into a first amendment to the SPA (the "Amendment") which amends certain of the terms of the SPA. Principally, the Amendment amends the "Outside Date" as defined therein from September 29, 2023 to December 31, 2023; amends the SPA to reduce the amount of cash to be paid at closing from \$4 million to \$2 million; amends the SPA to add to the items of business in relation to which Akerna will seek stockholder approval at a special meeting of the stockholders the issuance of shares of common stock of Akerna to MJA under the Amended and Restated Note; adds a new Section which provides that prior to closing under the SPA, MJA will work in good faith on a best efforts basis across multiple interested parties on behalf of and with the express approval of Akerna to secure for Akerna the highest purchase price possible for the shares of Ample. Akerna shall cause the proceeds from such sale to be included in the assets of MJA effective as of the closing. Notwithstanding the foregoing, in the event that the shares of Ample are sold to a third-party for a net purchase price above \$700,000, Akerna shall be entitled to retain all net proceeds in excess of \$700,000; provides that, within 3 business days of the Amendment, MJA will loan Akerna an additional \$500,000 to fund Akerna's working capital requirements; and provides that concurrently with the funding of the additional \$500,000 loan to Akerna, Akerna will issue and amend and restated convertible secured promissory note ("Amended and Restated Note") to MJA which amends and restates the Secured Promissory Note dated April 28, 2023 by and between Akerna and MJA (the "Original Note") to (A) increase the principal amount of the Original Note from \$1,000,000 to \$1,500,000, (B) provide for the forfeiture by MJA of the accrued and unpaid interest at the consummation of the transaction under the SPA and (C) provide that contemporaneous with and immediately prior to the consummation of the transactions under the SPA, the principal amount of the shall convert into such quantity of shares of common stock of the Company as equals (1) \$1,500,000, multiplied by (2) the 5-day volume weighted average price of the common stock of the Company as quoted on The Nasdaq Capital Market for the 5 trading days immediately preceding the date of the consummation of the transactions under the SPA; provided however, that in no case shall Akerna be required to issue to MJA such number of shares of common stock as would in the aggregate with all shares issued pursuant to the SPA and/or held or controlled by MJA exceed 19.99% of the number of issued and outstanding shares of common stock of the Seller on the date hereof without first obtaining the approval of stockholders of Akerna as required pursuant to the rules of the Nasdaq Stock Exchange.

On October 11, 2023, Akerna issued an amended and restated convertible secured promissory note ("Amended and Restated Note") to MJA which amends and restates the Secured Promissory Note dated April 28, 2023 by and between Akerna and MJA (the 'Original Note'), whereby Akerna promises to pay to the order of MJA or its registered assigns the amount of \$1,500,000. The Amended and Restated Note amended the Original Note to increase the principal amount of the Original Note from \$1,000,000 to \$1,500,000.

In connection to the MJA Note, the Security Agreement, and the Guaranty Agreement (collectively, "New Note Transaction Documents") and solely to permit Akerna to issue the MJA Note and execute and perform its obligations under the New Note Transaction Documents and a Subordination Agreement (as defined below), each of the holders (each, a "Holder") of the Senior Convertible Notes issued pursuant to a Securities Purchase Agreement dated October 5, 2021 ("2021 SPA") agreed to waive the prohibition on issuing indebtedness other than Permitted Indebtedness (as defined in the Senior Convertible Notes) pursuant to Section 14(b) 14(b) of the Senior Convertible Notes and the prohibition permitting Liens (as defined in the Senior Convertible Notes) to exist other than Permitted Liens (as defined in the Senior Convertible Notes) pursuant to Section 14(c) 14(c) of the Senior Convertible Notes and Section 5(g) 5(g)(v) of the 2021 SPA (the "Waiver"). In connection to the New Note Transaction Documents, MJ Acquisition, Akerna, and HT Investments MA LLC (the "Senior Agent", together with the Holders, the "Senior Creditors"), as collateral agent under the 2021 SPA, each on behalf of the respective Holders, entered into a subordination and intercreditor agreement (the "Subordination Agreement"), whereby the parties agreed that the payment of any and all obligations, liabilities and indebtedness of every nature of Akerna, its applicable subsidiary and/or affiliates from time to time owed to MJ Acquisition under the Subordinated Debt Documents (as defined in the Subordination Agreement) will be subordinate and subject in right and time of payment, to the prior payment in full of all obligations under the Senior Convertible Notes.

Pursuant to the Amended and Restated Note, Akerna's obligations under the Amended and Restated Note are to be secured pursuant to an Amended and Restated Security and Pledge Agreement entered into by and among Akerna, MJA and the other parties thereto dated October 11, 2023 (the "Amended and Restated Security Agreement"). The Amended and Restated Security Agreement amends and restates the Security Agreement entered into by and among Akerna, MJA and other parties thereto dated April 28, 2023 (the "Original Security Agreement") to reflect the entry into the Amended and Restated Note and change reference therein from the Original Note to the Amended and Restated Note.

Private Placement of Common Stock

On June 14, 2023, we entered into a transaction for a private investment in our public equity (the "PIPE Investment") whereby 1 million shares of Common Stock were issued to the investor at \$0.50 per share for total cash proceeds of \$0.5 million. The proceeds from the PIPE Investment were used to pay a termination fee and related expenses of \$0.2 million to POSaBIT in connection with the termination of the MJF-Ample MJF- Ample SPA and the remainder has been allocated for ongoing operating expenses.

Restructuring

In May 2022, we implemented a corporate restructuring initiative (the "Restructuring") that resulted in a charge of \$0.5 million associated with a reduction of our workforce by 59 employees, or approximately 33 percent of our headcount at that time. The charge associated with the Restructuring, all of which was settled in cash during the second quarter of 2022, was comprised primarily of severance benefits and related costs and was fully attributable to our continuing operations. Of the total amount incurred, \$0.3 million was included in Sales and marketing costs, approximately \$0.2 million was included in Product development costs and less than \$0.1 million was included in each of Cost of revenue and General and administrative expenses in our condensed consolidated statements of operations, respectively.

Financial Reporting and Classification

As a result of the corporate actions described above, 365 Cannabis and LCA (together, the "Discontinued Group") met the criteria to be considered "held for sale" as that term is defined in accounting principles generally accepted in the United States ("GAAP"). Accordingly, the assets and liabilities of these entities have been classified and reflected on our condensed consolidated balance sheets as "held for sale" as of December 31, 2022, and their results of operations and the effect of their sales have been classified as "discontinued operations" in the condensed consolidated statements of operations for the three and **six** **nine** months ended **June 30, 2023** **September 30, 2023** and 2022, respectively. Certain financial disclosures including major components of the assets and liabilities and results of operations of the Discontinued Group are provided in Note 12 to the condensed consolidated financial statements. Our core SMB and governmental business unit (MJF and Ample), the businesses for which we have committed to terminate operations (Viridian, Solo and Trellis) and our publicly-held parent holding company (Akerna Corp.) comprise our continuing operations. Collectively, these entities have been presented as continuing operations for all periods presented herein and until such time that stockholder approval is received for the Sale Transaction and the Merger.

The results of operations of our discontinued operations and the assets and liabilities of these operations that were held for sale and certain other additional disclosures are provided in Note 12 to the condensed consolidated financial statements.

Components of Results of Operations

Revenue

Historically, we have generated revenue from two primary sources: (1) software and (2) consulting services. Revenue from software comprised approximately 99 percent and **93** **97** percent of our revenue for the **six** **nine** months ended **June 30, 2023** **September 30, 2023** and 2022, respectively. While there was minimal revenue from consulting services during the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, approximately **7** **3** percent of our revenues were derived from consulting for the **six** **nine** months ended **June 30, 2022** **September 30, 2022**.

Software. Our software is solutioned for our key markets, SMB and government regulatory agencies. In these markets, software revenue is generated from subscriptions and services related to the use of our commercial software platforms, MJ Platform®, and our government regulatory platform, Leaf Data Systems®. Software contracts are generally quarterly or annual contracts paid monthly, quarterly, or annually in advance of service and cancellable upon 30 or 90 days' notice, although we do have many multi-year commercial software contracts. Leaf Data Systems® contracts are generally multi-year contracts payable annually or quarterly in advance of service. MJ Platform® and Leaf Data Systems® contracts generally may only be terminated early for breach of contract as defined in the respective agreements. Amounts that have been invoiced are initially recorded as deferred revenue or contract liabilities.

Consulting. Consulting services revenue is generated by providing solutions for prospective and current cannabis, hemp and CBD business operators in the pre-application of licensures and pre-operational phases of **development**. **development**. These services include application and business plan preparation as they seek licenses to be granted. Consulting projects completed during the pre-application phase generally solidify us as the software vendor of choice for subsequent operational phases once the operator is granted the license. As a result, our consulting revenue is driven as new emerging states pass legislation, and as our client-operators gain licenses.

Other Revenue. Our other revenue is derived primarily from point-of-sale hardware and other non-recurring revenue.

Cost of Revenue and Operating Expenses

Cost of Revenue. Our cost of revenue is derived from direct costs associated with operating our commercial and government regulatory software platforms and providing consulting services. The cost of revenue for our commercial and government regulatory platforms relates primarily to hosting and infrastructure costs and subcontractor expenses incurred in connection with certain government **contracts**. **contracts**. Consulting cost of revenue relates primarily to our employees' and consultants' salaries and other related compensation expenses. We record the cost of revenue using the direct cost method. This method requires the allocation of direct costs including support services and materials to the cost of revenue.

Product Development Expenses. Our product development expenses include salaries and benefits, nearshore contractor expenses, technology expenses, and other overhead related to the ongoing maintenance of our commercial and government regulatory software platforms and planning for new software **development**. **Product development**. Product development costs, other than software development expenses qualifying for capitalization, are expensed as incurred. Capitalized software development costs consist primarily of employee-related costs. We devote substantial resources to enhancing and maintaining our technology infrastructure, developing new and enhancing existing solutions, conducting quality assurance testing, and improving our core technology.

Sales and Marketing Expenses. Sales and marketing expense is primarily salaries and related expenses, including commissions, for our sales, marketing, and client service staff. We also categorize payments to partners and marketing programs as sales and marketing expenses. Marketing programs consist of advertising, events, such as trade shows, corporate communications, brand building, and product marketing activities. We plan to continue to invest in marketing and sales by expanding our domestic and international selling and marketing activities, building brand awareness, attracting new clients, and sponsoring additional marketing events. The timing of these marketing events will affect our marketing costs in a particular quarter. We defer the portion of sales commissions that is considered a cost of obtaining a new contract with a customer in accordance with the revenue recognition standard and amortize these deferred costs over the period of benefit, currently one year. We expense the remaining sales commissions as incurred. The rates at which sales commissions are earned varies depending on a variety of factors, including the nature of the sale (new, renewal, or add-on service offering), the type of service or solution sold, and the sales channel.

General and Administrative Expenses. Our general and administrative expenses include salaries and benefits and other costs of departments serving administrative functions, such as executives, finance and accounting, human resources, public relations and investor relations. In addition, general and administrative expense includes non-personnel costs, such as professional fees and other supporting corporate expenses not allocated to cost of revenue, product and development or sales and marketing.

Critical Accounting Policies and Estimates

Our critical accounting policies are disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022. Since the date of the Annual Report, there have been no material changes to our critical accounting policies.

Results of Operations for the Six Nine Months Ended June 30, 2023September 30, 2023 Compared to Six Nine Months Ended June 30, 2022September 30, 2022

The following table highlights our operating revenues and expenses attributable to our continuing operations for the six nine months ended June 30, 2023September 30, 2023 as compared to the six nine months ended June 30, 2022September 30, 2022:

	Nine Months Ended September 30,		Change Period over Period	
	2023	2022		
Revenues:				
Software	\$ 6,909,399	\$ 10,150,011	\$ (3,240,612)	(32)%
Consulting	46,000	618,809	(572,809)	(93)%
Other	17,710	30,315	(12,605)	(42)%
Total revenue	6,973,109	10,799,135	(3,826,026)	(35)%
Cost of revenues	2,988,688	4,175,056	(1,186,368)	(28)%
Gross profit	3,984,421	6,624,079	(2,639,658)	(40)%
Gross profit margin	57%	61%		
Operating expenses:				
Product development:	2,153,834	3,950,305	(1,796,471)	(45)%
Sales and marketing	1,997,996	4,984,983	(2,986,987)	(60)%
General and administrative	4,458,849	6,409,563	(1,950,615)	(30)%
Depreciation and amortization	746,967	4,475,485	(3,728,518)	(83)%
Impairment of long-lived assets	892,103	30,562,944	(29,670,841)	(97)%
Total operating expenses	10,249,849	50,383,281	(40,133,432)	(80)%
Loss from operations	\$ (6,265,427)	\$ (43,759,202)	\$ 37,493,774	(86)%

	Six Months Ended June 30,		Change Period over Period		
	2023	2022			
Revenues:					
Software	\$ 4,839,554	\$ 7,169,085	\$ (2,329,531)	(32)%	
Consulting	39,800	542,309	(502,509)	(93)%	
Other	11,203	23,362	(12,159)	(52)%	
Total revenue	4,890,557	7,734,756	(2,844,199)	(37)%	
Cost of revenues	2,013,977	2,698,270	(684,293)	(25)%	
Gross profit	2,876,580	5,036,486	(2,159,906)	(43)%	
Gross profit margin	59%	65%			
Operating expenses:					
Revenue	Product development:	1,504,765	2,991,119	(1,486,354)	(50)%
Revenue	Sales and marketing	1,431,849	4,030,224	(2,598,375)	(64)%

Software and administrative	3,057,848	4,580,348	(1,522,500)	(33)%
Depreciation and amortization	570,252	2,924,005	(2,353,753)	(80)%
Operating expenses	45,088,649	45,088,649	(85)%	(85)%
Loss from operations	(49,052,150)	(49,052,150)	(58,934,626)	(91)%

Total software revenue declined to \$4.8 million for the six nine months ended June 30, 2023 September 30, 2023 from \$7.2 million \$10.2 million for the six nine months ended June 30, 2022 September 30, 2022, for a decrease of \$2.3 million \$3.2 million, or 32% 32%. Software revenue accounted for substantially all of our revenues for the six nine months ended June 30, 2023 September 30, 2023 and approximately 93 percent 94 percent for the six nine months ended June 30, 2022 September 30, 2022. The decline is primarily attributable to (i) customer churn in our MJ Platform (\$0.4 0.6 million) and Ample (\$0.5 0.9 million) service offerings, (ii) lower continuing Leaf Data Systems revenues and lower platform revenues attributable to our two state clients and the transition of a key client's business from implementation fees to traditional subscription service from the 2022 period to the 2023 period (\$0.7 million) and (iii) the effects of the planned exit from our Soltrelics and Viridian platforms (\$0.7 1.1 million).

Consulting Revenue

In connection with the pending Sale Transaction and the Merger, we have de-emphasized our consulting services during the **six** **nine** months ended **June 30, 2023** **September 30, 2023**.

Other Revenue

Other revenue includes retail/resale revenue, which is generated from point-of-sale hardware, and other non-recurring revenues. Other revenue was less than one percent of total revenues for each of the **six** **nine** months ended **June 30, 2023** **September 30, 2023** and 2022, respectively.

Cost of Revenue

Our cost of revenue was **\$2.0 million** **\$3.0 million** for the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, compared to **\$2.7 million** **\$4.2 million** for the **six** **nine** months ended **June 30, 2022** **September 30, 2022**, reflecting a decline of **\$0.7 million**, **\$1.1 million**, or **25** **28** percent. The decrease was due primarily to the following: (i) lower hosting services and platform license costs of **\$0.9 million** **\$1.1 million** during the 2023 period and (ii) lower salary-related and contractor and consultant costs of **\$0.5 million** **\$0.7 million** in the 2023 period partially offset by the effect of a **\$0.5 million** **\$0.4 million** reversal of a legal contingency in the 2022 period and **\$0.2 million** **\$0.3 million** of costs capitalized during the 2022 period while no such costs were capitalized during the 2023 period.

2023 period.

Gross Profit

Gross profit was **\$2.9 million** **\$4.0 million** for the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, compared to **\$5.0 million** **\$6.6 million** for the **six** **nine** months ended **June 30, 2022** **September 30, 2022**, for a decrease of **\$2.2 million** **\$2.6 million**, or **43** **40** percent. The gross profit margin declined to **59** **57** percent during the 2023 period from **65** **61** percent in the 2022 period due primarily to a higher weighting of lower-margin contracts in the 2023 period as compared to the 2022 period as well as the effects of continuing to service the remaining products of Trellis, Solo and Viridian in the absence of any new revenue streams.

Operating Expenses

Product Development

Product development expense was **\$1.5 million** **\$2.2 million** for the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, compared to **\$3.0 million** **\$4.0 million** for the **six** **nine** months ended **June 30, 2022** **September 30, 2022**, representing a decrease of **\$1.5 million** **\$1.8 million**, or **50** **45** percent. The decrease is due primarily to lower salary-related and contractor expenses in the amount of **\$1.9 million** **\$3.6 million** and **\$0.2 million** of restructuring charges. These declines were primarily attributable to the actions that we took in the second quarter of 2022 associated with the Restructuring which reduced our overall headcount. The decline was partially offset by **\$0.6 million** **\$2.1 million** of costs capitalized during the 2022 period while no such costs were capitalized during the 2023 period.

Sales and Marketing

Sales and marketing expense was **\$1.4 million** **\$2.0 million** for the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, compared to **\$4.0 million** **\$5.0 million** for the **six** **nine** months ended **June 30, 2022** **September 30, 2022**, a decrease of **\$2.6 million**, **\$3.0 million**, or **64** **60** percent. These declines were due primarily to lower salary-related and contractor expenses in the amount of **\$2.0 million** **\$2.4 million**, lower software application costs and trade show and related promotional expenses of **\$0.4 million** **\$0.3 million** and lower restructuring charges of **\$0.3 million**. These declines were primarily attributable to the actions that we took in the second quarter of 2022 associated with the Restructuring which reduced our overall headcount. The decline was partially offset by **\$0.1 million** of higher stock-based compensation expense during the 2023 period.

General and Administrative

General and administrative expense was **\$3.1 million** **\$4.5 million** for the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, compared to **\$4.6 million** **\$6.4 million** for the **six** **nine** months ended **June 30, 2022** **September 30, 2022**, a decrease of **\$1.5 million**, **\$2.0 million**, or **33** **30** percent. The decrease was due primarily to the following: (i) lower overall compensation-related compensation-related and contractor costs of **\$0.4 million** **\$0.6 million** during the 2023 period attributable to lower overall headcount and lower stock-based and performance-based incentive compensation, (ii) lower recurring professional fees of **\$0.8 million** **\$0.9 million** during the 2023 period, (iii) lower occupancy and support costs of **\$0.2 million** **\$0.1 million** during the 2023 period as we operated on a 100 percent remote basis and (iv) lower bad debt and franchise and sales and use tax expenses of **\$0.5 million** **\$0.6 million**. These declines were partially offset by **\$0.4 million** **\$0.4 million** of professional fees and related costs associated with the Sales Transaction and the Merger.

Depreciation and Amortization

Depreciation and amortization expense decreased to \$0.6 million \$0.7 million for the six nine months ended June 30, 2023September 30, 2023 from \$2.9 million \$4.5 million for the six nine months ended June 30, 2022 September 30, 2022, representing a decrease of \$2.4 million \$3.7 million, or 80% 83%. The decrease is due to the substantial impairments of capitalized software and intangible assets that were recorded during 2022.

Impairment of Long-lived Assets

There

Impairment charges for goodwill (\$0.9 million) associated with Ample were no impairment charges recognized in the six nine months ended June 30, 2023September 30, 2023 while we impaired (i) goodwill associated with the Ample (\$10.7 million), Solo (\$11.2 million), Trellis (\$1.6 million) and Viridian (\$3.9 million) platforms and (ii) intangible assets (\$2.2 million) and capitalized software (\$1.0 million) associated with the Solo platform during the six nine months ended June 30, 2022 September 30, 2022.

Results of Operations for the Three Months Ended June 30, 2023September 30, 2023 Compared to Three Months Ended June 30, 2022September 30, 2022

The following table highlights our operating revenues and expenses attributable to our continuing operations for the three months ended June 30, 2023September 30, 2023 as compared to the three months ended June 30, 2022 September 30, 2022:

	Three Months Ended June 30,		Change	
	2023	2022	Period over Period	
Revenues:				
Software	\$ 2,242,792	\$ 3,366,333	\$ (1,123,541)	(33)%
Consulting	39,800	115,300	(75,500)	(65)%
Other	5,276	8,043	(2,767)	(34)%
Total revenue	2,287,868	3,489,676	(1,201,808)	(34)%
Cost of revenues	962,896	1,175,261	(212,365)	(18)%
Gross profit	1,324,972	2,314,415	(989,443)	(43)%
Gross profit margin		58%	66%	
Operating expenses:				
Product development:				
Sales and marketing	650,287	1,277,373	(616,086)	(48)%
General and administrative	650,258	1,272,091	(1,621,833)	(67)%
Revenues:				
Depreciation and amortization	1,495,947	2,658,017	(1,162,070)	(44)%
Impairment of long-lived assets	\$ 278,456	\$ 1,442,960	\$ (1,164,504)	(81)%
Other	6,200	15,115,625	(15,109,899)	(100)%
Total operating expenses	3,884,046	22,470,893	(19,586,935)	(66)%
Total revenue	2,082,553	3,064,379	(981,826)	(32)%
Cost of revenues	974,711	1,476,787	(502,076)	(34)%
Loss from operations	\$ (1,759,076)	\$ (20,156,468)	\$ 18,397,392)	(31)%
Gross profit	109,842	10,306,992		
Gross profit margin		53%	52%	
Operating expenses:				
Product development:				
Sales and marketing	649,070	959,185	(310,115)	(32)%
General and administrative	566,147	954,759	(388,612)	(41)%
Depreciation and amortization	1,401,101	1,830,663	(42,562)	(23)%
Impairment of long-lived assets	176,715	1,551,480	(1,374,765)	(89)%
Total operating expenses	892,103	—	892,103	100%
	3,685,136	5,296,088	(2,503,055)	(30)%
Loss from operations	\$ (2,577,294)	\$ (3,708,496)	\$ 1,131,202	(31)%
Revenue				
Software Revenue				

Software Revenue

Total software revenue declined to \$2.2 million \$2.1 million for the three months ended June 30, 2023September 30, 2023 from \$3.4 million \$3.0 million for the three months ended June 30, 2022 September 30, 2022, for a decreased decrease of \$1.1 million, \$0.9 million, or 33% 31%. Software revenue accounted for substantially all of our revenues for the three months ended June 30, 2023September 30, 2023 and approximately 96 percent 97 percent for the three months ended June 30, 2022 September 30, 2022. The decline is primarily attributable to (i) customer churn in our MJ Platform (\$0.2 million) and Ample (\$0.3 million) service offerings (ii) lower continuing Leaf Data Systems revenues and fewer change requests attributable to our two state clients and the transition of a key client's business from implementation fees to traditional subscription service from the 2022 period to the 2023 period (\$0.2 million) and (iii) the effects of the planned exit from our Solo, Trellis and Viridian platforms (\$0.4 million).

Consulting Revenue

In connection with the pending Sale Transaction and the Merger, we have de-emphasized our consulting services during the three months ended **June 30, 2023** **September 30, 2023**.

Other Revenue

Other revenue includes retail/resale revenue, which is generated from point-of-sale hardware, and other non-recurring revenues. Other revenue was less than one percent of total revenues for each of the three months ended **June 30, 2023** **September 30, 2023** and 2022, respectively.

Cost of Revenue

Our cost of revenue was \$1.0 million for the three months ended June 30, 2023, compared to \$1.2 million \$1.0 million for the three months ended **June 30, 2022** **September 30, 2023**, compared to \$1.5 million for the three months ended September 30, 2022, reflecting a decline of \$0.2 million \$0.5 million, or 18 percent. The decrease was due primarily to the following: (i) lower hosting services and platform license costs of \$0.5 million \$0.2 million during the 2023 period, 2023 period, (ii) lower salary-related and contractor and consultant costs of \$0.2 million \$0.2 million in the 2023 period 2023 period and (iii) lower support costs of \$0.1 million \$0.2 million during the 2023 period partially offset by the effect of a \$0.5 million reversal of a legal contingency in the 2022 period and \$0.1 million of costs capitalized during the 2022 period while no such costs were capitalized during the 2023 period.

Gross Profit

Gross profit was \$1.3 million for the three months ended June 30, 2023, compared to \$2.3 million \$1.1 million for the three months ended **June 30, 2022** **September 30, 2023**, compared to \$1.6 million for the three months ended September 30, 2022, for a decrease of \$1.0 million \$1.5 million or 43 percent. The gross profit margin declined increased to 58.53 percent during the 2023 period from 66.52 percent in the 2022 period due primarily to a higher weighting the actions that we took during 2023 associated with the de-emphasizing of lower-margin contracts in the 2023 period as compared to the 2022 period as well as the effects of continuing to service the remaining products of Trellis, Solo and Viridian in the absence of any new revenue streams consulting services which reduced our overall headcount.

Operating Expenses

Product Development

Product development expense was \$0.7 million \$0.6 million for the three months ended **June 30, 2023** **September 30, 2023**, compared to \$1.3 million \$0.9 million for the three months ended **June 30, 2022** **September 30, 2022**, representing a decrease of \$0.6 million \$0.3 million, or 48.32 percent. The decrease is due primarily to lower salary-related and contractor expenses in the amount of \$0.5 million \$0.2 million and the effect of \$0.2 million \$0.1 million of restructuring charges recorded in the 2022 period. These declines were primarily attributable to the actions that we took in the second quarter of 2022 during 2023 associated with the Restructuring planned exit from our Solo, Trellis and Viridian platforms which reduced our overall headcount. The decline was partially offset by \$0.1 million of higher stock-based compensation during the 2023 period.

Sales and Marketing

Sales and marketing expense was \$0.7 million \$0.6 million for the three months ended **June 30, 2023** **September 30, 2023**, compared to \$2.0 million \$1.0 million for the three months ended **June 30, 2022** **September 30, 2022**, a decrease of \$1.3 million \$0.4 million, or 67.41 percent. These declines were due primarily to lower salary-related and contractor expenses in the amount of \$0.9 million \$0.3 million, and lower software applications costs and trade show and related promotional expenses of \$0.1 million and lower restructuring charges of \$0.3 million. These declines were primarily attributable to the actions that we took in the second quarter of 2022 during 2023 associated with the Restructuring planned exit from our Solo, Trellis and Viridian platforms which reduced our overall headcount.

General and Administrative

General and administrative expense was \$1.5 million \$1.4 million for the three months ended **June 30, 2023** **September 30, 2023**, compared to \$2.7 million \$1.8 million for the three months ended **June 30, 2022** **September 30, 2022**, a decrease of \$1.2 million \$0.4 million, or 44.23 percent. The decrease was due primarily to the following: (i) lower overall compensation-related and contractor costs of \$0.1 million \$0.1 million during the 2023 period attributable to lower overall headcount and lower stock-based and performance-based incentive compensation, (ii) lower recurring professional fees of \$0.7 million \$0.2 million during the 2023 period, (iii) lower occupancy and support costs of \$0.1 million during the 2023 period as we operated on a 100 percent remote basis and (iv) lower credit loss expenses of \$0.3 million \$0.1 million. These declines were partially offset by \$0.1 million of professional fees and related costs associated with the Sales Transaction and the Merger.

Depreciation and Amortization

Depreciation and amortization expense decreased to \$0.3 million for the three months ended June 30, 2023 from \$1.4 million for the three months ended June 30, 2022, representing a decrease of \$1.1 million, or 81.89 percent. The decrease is due to the substantial impairments of capitalized software and intangible assets that were recorded during 2022.

Impairment of Long-lived Assets

Impairment charges for goodwill (\$0.9 million) associated with Ample were recognized in the three months ended September 30, 2023. There were no impairment charges recognized in the three months ended June 30, 2023 while we impaired goodwill associated with the Ample (\$2.7 million), Solo (\$4.9 million), Trellis (\$0.4 million) and Viridian (\$3.9 million) platforms during the six months ended June 30, 2022. In addition, we fully impaired the remaining intangible assets (\$2.2 million) and capitalized software (\$1.0 million) associated with the Solo platform during the six months ended June 30, 2022 September 30, 2022.

Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP.

Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. We attempt to compensate for these limitations by providing specific information regarding the GAAP items excluded from these non-GAAP financial measures.

Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

EBITDA and Adjusted EBITDA

We believe that EBITDA and Adjusted EBITDA, when considered with the financial statements determined in accordance with GAAP, are helpful to investors in understanding our performance and allows for comparison of our performance and credit strength to our peers. EBITDA and Adjusted EBITDA should not be considered alternatives to net loss as determined in accordance with GAAP as indicators of our performance or liquidity.

We define EBITDA as net loss (gain) before loss from discontinued operations, net of tax, interest expense, net, changes in fair value of convertible notes, changes in fair value of derivative liability, provision for income taxes, and depreciation and amortization. We calculate Adjusted EBITDA as EBITDA further adjusted to exclude the effects of the following items for the reasons set forth below:

- impairment of long-lived assets, as this is a non-cash, non-recurring item, which affects the comparability of results of operations and liquidity;
- stock-based compensation expense, because this represents a non-cash charge and our mix of cash and stock-based compensation may differ from other companies, which affects the comparability of results of operations and liquidity;
- cost incurred in connection with strategic transactions including the Sale Transaction, the Merger, the termination of the MJF-Ample SPA with POSaBIT and business combinations that are required to be expensed as incurred in accordance with GAAP, because such costs are specific to the complexity and size of the underlying transactions and these costs are not reflective of our ongoing operations;
- restructuring charges, which includes severance costs to terminate employees in functions that have been eliminated as we believe these costs are not representative of operating performance;

The reconciliation of net loss to EBITDA and Adjusted EBITDA is as follows:

	Three Months Ended June 30,		Three Months Ended September 30,	
	2023	2022	2023	2022
Net loss	\$ (3,081,951)	\$ (29,565,947)	\$ (2,594,938)	\$ (2,305,536)
Adjustments:				
Loss from discontinued operations, net of tax	—	9,064,379	—	(2,868,460)
Interest expense	227,055	212,987	202,644	395,422
Change in fair value of convertible notes	893,000	294,000	(185,000)	1,113,000
Change in fair value of derivative liability	—	(33,845)	—	(2,256)
Income tax benefit	—	(128,042)	—	(40,666)
Depreciation and amortization	278,456	1,442,560	176,715	1,551,480
EBITDA	\$ (1,683,440)	\$ (18,713,908)	\$ (2,400,579)	\$ (2,157,016)
Impairment of long-lived assets	—	15,115,843	892,103	—
Stock-based compensation expense	108,476	131,322	100,096	202,575
Strategic transaction and merger related costs	642,637	6,062	163,856	71,156
Non-recurring financing fees	—	325,410	—	59,094
Restructuring charges	—	493,409	—	59,094
Adjusted EBITDA	\$ (932,327)	\$ (2,641,862)	\$ (1,244,524)	\$ (1,824,191)

	Six Months Ended June 30,	
	2023	2022
Net loss	\$ (5,556,579)	\$ (51,518,840)
Adjustments:		
(Gain) loss from discontinued operations, net of tax	(97,203)	9,805,341
Interest expense	714,371	213,727
Change in fair value of convertible notes	1,048,457	1,727,000
Change in fair value of derivative liability	—	(51,896)
Income tax benefit	—	(227,486)
Depreciation and amortization	570,252	2,924,005
EBITDA	\$ (3,320,702)	\$ (37,128,149)
Impairment of long-lived assets	—	30,562,944
Stock-based compensation expense		Nine Months Ended September 30,
Strategic transaction and merger related costs		206,733
Non-recurring financing fees		443,437
Net loss	\$ (8,151,516)	\$ (53,822,928)
Restructuring charges	45,521	493,468
Adjusted EBITDA		
(Gain) loss from discontinued operations, net of tax	115,398	\$ (2,121,852)
Interest expense	917,015	609,150
Change in fair value of convertible notes	863,457	2,840,000
Change in fair value of derivative liability	—	(54,153)
Income tax benefit	—	(268,152)
Depreciation and amortization	746,967	4,475,485
EBITDA	\$ (5,508,679)	\$ (39,283,717)
Impairment of long-lived assets	892,103	30,562,944
Stock-based compensation expense	306,830	646,012
Strategic transaction and merger related costs	897,850	429,601
Restructuring charges	45,521	552,563
Adjusted EBITDA	\$ (3,366,375)	\$ (7,092,597)

Going Concern and Management's Management's Liquidity Plans

In accordance with the Financial Accounting Standards Board's ("FASB") standard on going concern, Accounting Standard Update ("ASU") ("ASU") No. 2014-15, 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15" 2014-15), we assess going concern uncertainty in our consolidated financial statements to determine if we have sufficient cash, cash equivalents and working capital on hand, including marketable equity securities, and any available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and our ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions regarding implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable that such implementations can be achieved and we have the proper authority to execute them within one year from the date the consolidated financial statements are issued.

The accompanying condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. However, since our inception in 2019 we have incurred recurring losses from operations, used cash from operating activities, and relied on capital raising transactions to continue ongoing operations. As of June 30, 2023 September 30, 2023, we had a working capital deficit of \$9.7 million \$11.2 million with \$1.3 million \$0.2 million in cash available to fund future operations including \$0.5 million in cash that was classified as "restricted" as of June 30, 2023. The restrictions on those accounts were eliminated in July 2023 and the amounts became fully available for our use as working capital. Furthermore, on March 22 and 23, 2023, respectively, we received two notices (the "Notices") from The Nasdaq Stock Market LLC ("Nasdaq") indicating (i) that the bid price of the Company's Common Stock is not currently in compliance with the requirement to maintain a minimum bid price of \$1.00 \$1.00 per share (the "Bid Price Notice") and (ii) the Company's stockholders' equity is below the minimum listing standard requirement of \$2.5 million for continued listing on the Nasdaq (the "Stockholders Equity Notice"). The Notices have no immediate effect on the continued listing status of our Common Stock on the Nasdaq, and, therefore, our listing remains fully effective. We are provided a compliance period of 180 calendar days from the date of the Bid Price Notice, or until September 18, 2023, to regain compliance with the minimum closing bid requirement. Regarding the Stockholders Equity Notice, we submitted the required compliance plan to the listings staff of the Nasdaq on May 8, 2023 which was conditioned upon the successful completion of the Merger. On June 15, 2023, we received a letter from Nasdaq granting an extension through September 19, 2023 to complete the Merger. The terms On September 19, 2023, the Company received a determination letter (the "Determination Letter") from the Staff stating that it had not regained compliance with the minimum bid price requirement or the minimum listing standard requirement of \$2.5 million and is not eligible for an additional 180-day period to regain compliance. Further, the Determination Letter indicate that unless the Company requests an appeal of this determination the trading of the extension include: (i) receiving approval Company's common stock will be suspended at the opening of business on September 28, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from Nasdaq to list the post-Merger entity, (ii) completion of the Merger transaction listing and (iii) meeting all of the initial and continued listing requirements for the registration on The Nasdaq Capital Market. Collectively, these factors raise substantial doubt regarding The Company had a deadline to appeal the ability Staff's determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, no later than 4:00 pm Eastern Time on September 26, 2023. The Company successfully submitted a hearing request on September 25, 2023 and received a hearing date of November 9, 2023. This Hearing will stay any delisting or suspension action by the Company to continue as a going concern for the twelve months following Staff pending the issuance of our condensed consolidated financial statements.

The Panel's decision. The Company's common stock will remain listed on Nasdaq pending the outcome of the Hearing. There can be no assurance that the Panel will grant the Company's request for continued listing, however on November 2, 2023 the Company received a document from the Nasdaq Staff indicating, based on their review it appears that the post-transaction referring to the Akerna Merger Jersey will demonstrate compliance with the initial listing requirements, only in the event that the transaction successfully closes.

As described above and in Note 1 to the consolidated financial statements, we have committed to the Sale Transaction to complete our intended exit from the SaaS industry and to the Merger as the most favorable strategic alternative for our stockholders. There can be no assurance that we will be successful in executing and completing the Sale Transaction and the Merger and obtaining sufficient funding, if necessary, on terms acceptable to us to fund continuing operations through the anticipated closing of the aforementioned transactions, if at all. Our ability to continue as a going concern is dependent upon our ability to successfully execute the aforementioned transactions. Despite the comprehensive scope of our collective plans, the inherent risks associated with their successful execution are not sufficient to overcome substantial doubt about our ability to continue as a going concern for one year from the date of issuance of our consolidated financial statements. Accordingly, if we are unable to execute our plans within the timeframe described above, we may have to reduce or otherwise curtail our continuing operations which could significantly and adversely affect our results of operations or we may determine to dissolve and liquidate our assets. If we fail to meet the financial covenants of the Senior Convertible Notes and cannot obtain a waiver from such provisions or otherwise come to an agreement with the holders of the Senior Convertible Notes, such holders may declare a default which could subject our assets to seizure and sale, negatively impacting our business. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Cash Flows

Our cash and restricted cash balance was \$1.3 million \$0.2 million as of June 30, 2023 September 30, 2023. Cash flow information is as follows:

	<i>Six Months Ended June 30,</i>	
	<i>2023</i>	<i>2022</i>
Cash (used in) provided by:		
<i>Operating activities</i>	\$ (4,090,628)	\$ (7,187,445)
<i>Investing activities</i>	600,000	(1,364,503)
<i>Financing activities</i>	(3,491,409)	(666,989)
Effect of change in exchange rates on cash and restricted cash		
	52,919	9,225
Net decrease in cash and restricted cash	<u>\$ (6,433,122)</u>	<u>\$ (702,712)</u>
Cash (used in) provided by:		
Operating activities	\$ (5,206,372)	\$ (10,450,906)
Investing activities	600,000	(2,951,412)
Financing activities	(3,417,405)	8,494,699
Effect of change in exchange rates on cash and restricted cash	50,099	(35,984)
Net decrease in cash and restricted cash	<u>\$ (7,973,678)</u>	<u>\$ (4,943,063)</u>

Operating Activities

Our largest source of operating cash is cash collections from our customers for subscriptions to our products. Our primary uses of cash in operating activities are for employee-related expenditures, marketing expenses and third-party hosting costs. Net cash used in operating activities is impacted by our net loss adjusted for certain non-cash items, including depreciation and amortization expenses, impairments of long-lived assets, changes in the fair value of convertible notes and derivative liabilities, stock-based compensation, deferred income taxes, among other non-cash items as well as the effect of changes in operating assets and liabilities.

Net cash used in operating activities declined to \$4.1 million \$5.2 million during the six nine months ended June 30, 2023 September 30, 2023 from \$7.2 million \$10.4 million during the six nine months ended June 30, 2022 September 30, 2022 due primarily to the elimination of costs associated with salaries and benefits and related support costs as a result of the actions taken during the second quarter of 2022 associated with the Restructuring which lowered our overall employee headcount. In addition, the 2023 period only includes one month of cash utilization by our discontinued operations 365 Cannabis and LCA and lower activity levels for all of our continuing operations including Solo, Trellis and Viridian which we have committed to winding down and terminating terminated prior to the Merger and Sale Transaction.

Investing Activities

Our primary investing activities have consisted of capitalization of internal-use software necessary to deliver significant new features and functionality in our platform which provides value to our customers. Other investing activities include cash outflows related to purchases of property and equipment, and from time-to-time, the cash paid for asset and business acquisitions as well as cash received from the disposition of assets and business units.

Net cash provided by investing activities totaled \$0.6 million during the six nine months ended June 30, 2023 September 30, 2023, as a result of sale of the 365 Cannabis and LCA business units in January 2023 2023. Net cash used by investing activities during the six nine months ended June 30, 2022 September 30, 2022, was \$1.4 million \$3.0 million which was related to the development of our software products, products.

Financing Activities

Our financing activities consist primarily of proceeds from issuance of our common stock, including those through our ATM Program, repayments attributable to the Senior Convertible Notes and the value of shares withheld from the vesting of certain stock-based compensation awards.

During the six nine months ended June 30, 2023 September 30, 2023 and 2022 we made \$4.9 million and \$1.5 million of principal payments on the Senior Convertible Notes, respectively, respectively. The funds for the payments in the 2023 period were sourced from the proceeds of the sale of our discontinued operations and from releases from the restricted cash accounts while the payments in the 2022 period were sourced from cash on hand and from \$0.8 million \$0.8 million of proceeds received from the issuance of shares under our ATM program. In June 2023, we completed the PIPE Investment which provided proceeds of \$0.5 million. In May 2023, we received proceeds of \$1.0 million from the issuance of the MJA Note. During each of the six nine months ended June 30, 2023 September 30, 2023 and 2022, the value of shares withheld for income taxes from the vesting of stock-based compensation awards was less than \$0.1 million, respectively.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

36

Item 4. Controls and Procedures.**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the "Exchange Act")) that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is processed, recorded, summarized, and reported within the time periods specified in the Security and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

We have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act) as of **June 30, 2023** **September 30, 2023** with the participation, and under the supervision, of our management, including our Chief Executive Officer and Chief Financial Officer. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of **June 30, 2023** **September 30, 2023**, our disclosure controls and procedures were ineffective in ensuring that: (i) information required to be disclosed by us in reports that we file or submit to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in applicable rules and forms and (ii) material information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for accurate and timely decisions regarding required disclosure.

Material Weakness

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. Pursuant to our management's review of disclosure controls and procedures and internal control over financial reporting, management determined that the following material weakness in our internal control over financial reporting and prevented management from determining that our disclosure controls and procedures and internal control over financial reporting were effective as of the end of the period covered by this report:

- | The Company's internal control over financial reporting pertaining to certain key process areas of financial reporting were not properly designed and/or operating effectively.

37

Remediation Efforts

We are in the process of executing our remediation plans to address the material weakness described above. As of **June 30, 2023** **September 30, 2023**, we have:

- Hired additional experienced resources with the appropriate skills to fill key accounting functions.
- Engaged an outside firm to assist in the overall evaluation and documentation of the design and operating effectiveness of our internal controls over financial reporting and have remediated past deficiencies in the design of our internal control framework for certain key process areas including revenue, capitalized software, business combinations, intangibles, goodwill, stock-based compensation, general financial reporting, and information technology.
- Developed a long-term plan to both (i) complete the remediation of the design of our internal control over financial reporting for our remaining process areas, and (ii) begin the remediation of the deficiencies in operating effectiveness of our internal controls over financial reporting across all process areas.

We believe these actions and the improvements we expect to achieve, when fully implemented, will strengthen our internal control over financial reporting and remediate the material weaknesses. However, the material weaknesses will not be considered fully remediated until the applicable controls operate for a sufficient period of time for management to test the results for operating effectiveness. While no assurance can be provided, the Company believes it will make further progress in remediating these material weaknesses during 2023.

Notwithstanding the material weakness, management has concluded that the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q present fairly, in all material respects, our financial position, results of operations, and cash flows in conformity with GAAP.

Changes in Internal Control over Financial Reporting

During the most recently completed fiscal quarter, there have been no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Management recognizes that a control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future **conditions**; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II- Other Information

Item 1. Legal Proceedings.

From time to time, we may be subject to legal proceedings arising in the ordinary course of business. Regardless of the outcome of any existing or future litigation, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

The information required with respect to this item can be found under "Commitments and Contingencies" in Note 9 to our condensed consolidated financial statements included elsewhere in this Form 10-Q and is incorporated by reference into this Item 1.1.

Item 1A. Risk Factors.

Except for the additional risk factors set forth below, there have been no material changes to our Risk Factors as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 20, 2023 March 20, 2023.

Risks Related to Our Common Stock

If our common stock is delisted from Nasdaq, the liquidity and price of our common stock could decrease and our ability to obtain financing could be impaired.

On March 22, 2023, we received a notification letter from The Nasdaq Stock Market stating that we are not in compliance with the minimum bid price requirement, which requires our listed securities to maintain a minimum bid price of \$1.00 per share (the "Minimum Bid Price Requirement"). The notification stated that we have a compliance period of 180 calendar days, or until September 18, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time during this 180-day 180-day compliance period the closing bid price of our common stock is at least \$1.00 per share for a minimum of ten consecutive business days, then the Nasdaq Stock Market will provide us with written confirmation of compliance and the matter will be closed.

If compliance cannot be demonstrated by September 18, 2023, we may be eligible for additional time. To qualify, we will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards on the Nasdaq Capital Market (except the bid price requirement). In addition, we would be required to provide written notice of our intention to cure the minimum bid price deficiency during this second 180-day 180-day compliance period by effecting a reverse stock split, if necessary. If we are not granted an additional 180-day 180-day compliance period, then Nasdaq will provide written notification that our securities will be subject to delisting. At that time, we may appeal the determination to delist our securities to a Nasdaq hearings panel. There can be no assurance that we will regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with the other listing requirements. requirements.

On March 23, 2023, we received notice from The Nasdaq Stock Market advising us that we are not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders' equity of at least \$2,500,000 (the "Stockholders' Equity Requirement"). In our Annual Report on Form 10-K10-K for the year ended December 31, 2022, Akerna reported stockholders' equity of (\$4,825,528), which is below the Stockholders' Equity Requirement for continued listing. Through June 30, 2023 September 30, 2023, our stockholders' equity has declined further to a deficit of (\$8,162,393) 8,306,961.

Pursuant to the notice, Nasdaq provided us 45 calendar days, or until May 8, 2023, May 8, 2023, to submit to Nasdaq a plan to regain compliance. We submitted our plan on May 8, 2023 May 8, 2023 which was conditioned upon the successful completion of the Merger. On June 15, 2023, we received a letter from Nasdaq granting an extension through September 19, 2023 to complete the Merger. The terms of the extension include: (i) receiving approval from Nasdaq to list the post-Merger entity, (ii) completion of the Merger transaction and (iii) meeting all of the initial and continued listing requirements for the Nasdaq Capital Market.

On September 19, 2023, the Company received a determination letter (the "Determination Letter") from the Staff stating that it had not regained compliance with the minimum bid price requirement or the minimum listing standard requirement of \$2.5 million and is not eligible for an additional 180-day period to regain compliance. Further, the Determination Letter indicate that unless the Company requests an appeal of this determination the trading of the Company's common stock will be suspended at the opening of business on September 28, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on The Nasdaq Capital Market. The Company had a deadline to appeal the Staff's determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, no later than 4:00 pm Eastern Time on September 26, 2023. The Company successfully submitted a hearing request on September 25, 2023 and received a hearing date of November 9, 2023. This Hearing will stay any delisting or suspension action by the Staff pending the issuance of the Panel's decision. The Company's common stock will remain listed on Nasdaq, pending the outcome of the Hearing. There can be no assurance that our the Panel will grant the Company's request for continued listing, however on November 2, 2023 the Company received a document from the Nasdaq Staff indicating, based on their review it appears the that the post-transaction (referring to the Akerna Merger) entity will demonstrate compliance with the initial listing requirements, only in the event that the transaction successfully closes.

There can be no assurance that the Company's plan as presented to the Panel will be accepted by the Panel or that, if it is, we the Company will be able to regain compliance with the applicable Nasdaq listing requirements, or that a Panel will stay the suspension of the Company's securities. If our plan the Company's securities are delisted from Nasdaq, it could be more difficult to regain compliance if not accepted, buy or if it is and Akerna does not regain compliance within 180 days from sell the date of Nasdaq's letter, or if Akerna fails to satisfy another Nasdaq requirement for continued listing, Nasdaq could provide notice that our Company's common stock will become subject to delisting. In such event, Nasdaq rules would permit us to appeal obtain accurate quotations, and the decision to reject our proposed compliance plan or any delisting determination to a Nasdaq Hearings Panel. The hearing request would stay any suspension or delisting action pending the conclusion price of the hearing process Company's common stock could suffer a material decline. Delisting could also impair the Company's ability to raise capital and/or trigger defaults and penalties under outstanding agreements or securities of the expiration of any additional extension period granted by the panel following the hearing. Company.

39

Risks Related to the Proposed Sale Transaction

Certain provisions of the SPA may discourage third parties from submitting alternative proposals for the subsidiaries and assets being sold, including proposals that may be superior to the arrangements contemplated by the SPA.

The SPA contains "no-shop" restrictions on Akerna's ability to solicit, initiate or knowingly encourage third party proposals relating to alternative transactions or to provide information to, or engage in discussions with, a third party in relation to an alternative transaction, subject to the ability of our Board of Directors to change their recommendation and terminate the SPA in accordance with their fiduciary duties. Before our Board Directors may change its recommendation to stockholders or terminate the SPA to accept a Superior Offer (as defined in the SPA), Akerna must, among other things, provide MJ Acquisition with notice. Upon the termination of the SPA, including in connection with a Superior Offer, we may be required to pay up to \$140,000 as a termination fee plus \$60,000 in reasonable fees and expenses.

These provisions could discourage a potential third party acquiror from considering or proposing an acquisition transaction, even if it were prepared to pay a higher price than what would be received in the Sale Transaction. These provisions might also result in a potential third party acquiror proposing to pay a lower price than it might otherwise have proposed to pay because of the added expense of the \$140,000 termination fee and \$60,000 in fees and expenses that may become payable.

If the SPA is terminated and we determine to seek another business combination, we may not be able to negotiate a transaction with another party on terms comparable to, or better than, the terms of the Purchase Agreement.

40

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Except as previously reported in our Current Report on Form 8-K, we did not undertake any unregistered sales of our equity securities during the quarter ended **June 30, 2023** **September 30, 2023**.

During the quarter ended **June 30, 2023** **September 30, 2023**, the Company did not repurchase any of its Common Shares.

Item 3. Defaults Upon Senior Securities.

None.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits

2.1+	Agreement and Plan of Merger, dated as of January 27, 2023, by and among Akerna Corp., Merger Sub and Gryphon (incorporated by reference to Exhibit 2.2 on Current Report on Form 8-K filed by Akerna on January 27, 2023)
2.2+	Securities Purchase Agreement, dated April 28, 2023, by and among Akerna, Akerna Exchange and MJA (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Akerna on May 1, 2023)
2.3	Form of Voting and Support Agreement by and between certain stockholders named therein and Gryphon (incorporated by reference to Exhibit 2.4 on Current Report on Form 8-K filed by Akerna on January 27, 2023)
2.4	Form of Lender Support Letter for Merger (incorporated by reference to Exhibit 2.6 on Current Report on Form 8-K filed by Akerna on January 27, 2023)
2.5	Form of Voting and Support Agreement, dated April 28, 2023, by and between certain stockholders named therein and MJA (incorporated by reference to Exhibit 2.4 to the Current Report on Form 8-K filed by Akerna on May 1, 2023)
2.6	Form of Lender Support Letter for Sale Transaction (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Akerna by Akerna on May 1, 2023)
2.7	First Amendment to Agreement and Plan of Merger dated April 28, 2023 by and among Akerna, Akerna Merger Co. and Gryphon Digital Mining, Inc. (incorporated by reference to Exhibit 2.5 to the Current Report on Form 8-K filed by Akerna on May 1, 2023)
2.8	Second Amendment to the Agreement and Plan of Merger by and between Akerna Corp., Akerna Merger Co. and Gryphon dated June 14, 2023 (incorporated by reference to Exhibit 4.1 to the registrant's Current Report on Form 8-K filed on June 15, 2023)
3.1	Amended and Restated Certificate of Incorporation of Akerna Corp. (incorporated by reference to Exhibit 3.1 on Quarterly Report on Form 10-Q filed by Akerna on November 14, 2022)
3.2	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Quarterly Report on Form 10-Q filed by Akerna on November 14, 2022)
3.3	Certificate of Designation for the Special Voting Share (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K 8-K filed by Akerna on July 8, 2020)
3.4	Certificate of Designation of Preference, Rights and Limitations of Series A Convertible Redeemable Preferred Stock (incorporated by reference to Exhibit 3.1 to Akerna's Current Report on Form 8-K filed with the Commission on October 3, 2022)
3.5	Certificate of Designation of Preference, Rights and Limitations of Series B Convertible Redeemable Preferred Stock (incorporated by reference to Exhibit 3.2 to Akerna's Current Report on Form 8-K filed with the Commission on October 3, 2022)
4.1	Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Akerna's Registration Statement on Form S-4 (File No. 333-228220))
4.2	Specimen Warrant Certificate (incorporated by reference to Exhibit 4.2 to Akerna's Registration Statement on Form S-4 (File No. 333-228220))
4.3	Form of Warrant Agreement (incorporated by reference to Exhibit 4.3 on Current Report on Form 8-K filed by Akerna on June 21, 2019)
4.4	Stock Purchase Agreement, dated September 13, 2021, relating to the 365 Cannabis acquisition (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Akerna on September 21, 2021)
4.5	Securities Purchase Agreement, dated October 5, 2021 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Akerna on October 5, 2021)
4.6	Form of Secured Convertible Notes (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by Akerna on October 5, 2021)
4.7	Form of Security Agreement (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by Akerna on October 5, 2021)
4.8	Form of Guaranty Agreement (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by Akerna on October 5, 2021)
4.9	Amendment and Waiver Agreement dated June 30, 2022 to the Securities Purchase Agreement dated October 5, 2021 (incorporated by reference to Exhibit 4.1 to the Quarterly Report on Form 10-Q as filed by Akerna on August 12, 2022)
4.10	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.10 to Akerna Corp's Form S-1 as filed with the Commission on June 29, 2022)
4.11	Form of Warrant (incorporated by reference to Exhibit 4.9 to Akerna Corp's post-effective amendment to Form S-1 as filed with the Commission on July 1, 2022)
4.12	Form of Underwriter's Warrants (incorporated by reference to Exhibit 4.11 to Akerna Corp's post-effective amendment to Form S-1 as filed with the Commission on July 1, 2022)
4.13	Waiver dated September 27, 2022 by and between Akerna Corp. and the Holders in accordance with the Securities Purchase Agreement dated October 5, 2021 (incorporated by reference to Exhibit 4.1 to Akerna Corp.'s Quarterly Report on Form 10-Q as filed with the Commission on November 14, 2022)
4.14	Amendment No. 1 to the Exchangeable Share Support Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K as filed by Akerna on November 18, 2022)

4.15+	Form of Secured Promissory Note, dated April 28, 2023, by and among Akerna, Akerna Exchange, and MJA (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Akerna on May 1, 2023)
4.16+	Form of Security and Pledge Agreement, by and among Akerna, MJA and the other parties thereto dated April 28, 2023 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by Akerna on May 1, 2023)
4.17	Form of Guaranty Agreement, by and among certain subsidiaries of Akerna and MJA, dated April 28, 2023 (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by Akerna on May 1, 2023)
4.18	Subordination and Intercreditor Agreement, by and among MJA, Akerna, and HT Investments MA LLC, dated April 28, 2023 (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by Akerna on May 1, 2023)
4.19	Waiver, by and among Akerna and certain note holders, dated April 28, 2023 (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed by Akerna on May 1, 2023)
4.20	Waiver, by and among Akerna and certain note holders, dated June 14, 2023 (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by Akerna on June 15, 2023)
10.1	Securities Purchase Agreement by and between Akerna Corp. and the investor named therein dated June 14, 2023 (incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on June 15, 2023)
10.2	Registration Rights Agreement by and between Akerna Corp. and the investor named therein dated June 14, 2023 (incorporated by reference to Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on June 15, 2023)
31.1	Section 301 Certification of Principal Executive Officer
31.2	Section 302 Certification of Principal Financial Officer
32.1	Section 906 Certification of Principal Executive Officer
32.2	Section 906 Certification of Principal Financial Officer
101	XBRL (Extensible Business Reporting Language). The following materials from Akerna Corp's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 September 30, 2023, tagged in XBRL: (i) condensed consolidated balance sheets; sheets; (ii) condensed consolidated statements of operations; operations; (iii) condensed consolidated statements of comprehensive income; income; (iv) condensed consolidated statements of cash flows; flows; and (v) notes to condensed consolidated financial statements.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

⁺ The exhibits and schedules to this Exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant hereby agrees to furnish a copy of any omitted schedules to the Commission upon request.

SIGNATURES

In accordance with the requirements of Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

By: /s/ Jessica Billingsley

Jessica Billingsley,
Chief Executive Officer and Director
(*Principal Executive Officer*)

August 14, 2023

November 14, 2023

By: /s/ L. Dean Ditto

L. Dean Ditto,
Chief Financial Officer

(*Principal Financial and Accounting Officer*)

August**November 14, 2023**

CERTIFICATION PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Jessica Billingsley, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Akerna Corp.
1. I have reviewed this Quarterly Report on Form 10-Q of Akerna Corp.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

- a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2023 November 14, 2023

By: /s/ Jessica Billingsley

Jessica Billingsley,
Chief Executive Officer and Director
(Principal Executive Officer)

Exhibit 31.2

**CERTIFICATION PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002**

I, L. Dean Ditto, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Akerna Corp.
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

1. I have reviewed this Quarterly Report on Form 10-Q of Akerna Corp.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

- d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2023 November 14, 2023

By: /s/ L. Dean Ditto
 L. Dean Ditto,
 Chief Financial Officer

(Principal Financial and Accounting Officer)

Exhibit 32.1

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)**

*In connection with the Quarterly Report of Akerna Corp. (the "Company") on Form 10-Q for the quarterly period ended **June 30, 2023** **September 30, 2023** as filed with the Securities and Exchange Commission on the date hereof (the "Quarterly Report"), I, Jessica Billingsley, Chief Executive Officer, do hereby certify, to my knowledge:*

- (1) The Quarterly Report fully complies with the requirements of Section 13(a), or 15(d) of the Securities Exchange Act of 1934; and**
 - (2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.**
- (1) The Quarterly Report fully complies with the requirements of Section 13(a), or 15(d) of the Securities Exchange Act of 1934; and

- (2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: August 14, 2023 November 14, 2023

By: /s/ Jessica Billingsley
 Jessica Billingsley,
 Chief Executive Officer and Director
(Principal Executive Officer)

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)**

*In connection with the Quarterly Report of Akerna Corp. (the "Company") on Form 10-Q for the quarterly period ended **June 30, 2023** **September 30, 2023** as filed with the Securities and Exchange Commission on the date hereof (the "Quarterly Report"), I, L. Dean Ditto, Chief Financial Officer, do hereby certify, to my knowledge:*

- (1) The Quarterly Report fully complies with the requirements of Section 13(a), or 15(d) of the Securities Exchange Act of 1934; and**
 - (2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.**
- (1) The Quarterly Report fully complies with the requirements of Section 13(a), or 15(d) of the Securities Exchange Act of 1934; and

- (2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: August 14, 2023 November 14, 2023

By: /s/ L. Dean Ditto
 L. Dean Ditto,
 Chief Financial Officer
(Principal Financial and Accounting Officer)

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2023, Refinitiv. All rights reserved. Patents Pending.